Mountain View, CA, Oct 23, 2026 - (JCN Newswire) - Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of its New Drug Application (NDA) for oxylanthanum carbonate (OLC), the Company's investigational oral phosphate binder for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. The NDA was resubmitted following a Complete Response Letter (CRL) received in June 2026. The FDA has deemed the OLC resubmission a Class II with a six-month review period from the resubmission date, and set a Prescription Drug User Fee Act (PDUFA) target action date of March 25, 2027.
Unicycive Therapeutics, Inc. is a B2i Digital Featured Company. See the company's in-depth profile at: https://b2idigital.com/unicycive-therapeutics.
"We are pleased that the FDA has accepted the resubmission of our NDA for OLC and assigned a PDUFA date," said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. "This resubmission includes CMC data from a new third-party drug product manufacturing vendor. The new vendor's facility was last inspected by the FDA in March 2024 and received 'No Action Indicated' status. We hope to continue working with the FDA toward potential approval of this important medication to patients with CKD on dialysis who need additional treatment options for managing hyperphosphatemia."
The Company does not know whether the FDA will decide to conduct a pre-approval inspection of the new third-party DP vendor. Additionally, if the original third-party manufacturing vendor is inspected in the near term and finds that its facility complies with current Good Manufacturing Practice (cGMP), the Company plans to seek FDA alignment on a shorter approval timeline.
The Company resubmitted the NDA following the second CRL, which cited deficiencies previously identified at the original third-party manufacturer of the drug product, which the FDA had not been able to re-inspect during the prior submission review.
The timing and outcome of any FDA inspection of the original third-party vendor will be determined solely by the FDA.
The NDA is supported by data from three clinical studies (a Phase 1 study in healthy volunteers, a bioequivalence study in healthy volunteers, and a tolerability study of OLC in CKD patients on dialysis), multiple preclinical studies, as well as CMC data. The FDA did not raise any concerns regarding OLC's preclinical or clinical data, including safety data, included in the original NDA submission.
About Oxylanthanum Carbonate
OLC is an investigational oral phosphate binder that leverages proprietary nanoparticle technology to deliver high phosphate binding potency, reducing the number and size of pills that patients must take to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. Its potential best-in-class profile may have meaningful patient adherence benefits over currently available treatment options as it requires a lower pill burden. Unicycive is seeking FDA approval of OLC via the 505(b)(2) regulatory pathway. OLC is protected by a strong global patent portfolio including issued patents on composition of matter with exclusivity until 2031, and with the potential for patent term extension until 2035.
About Hyperphosphatemia
Hyperphosphatemia is a serious medical condition that occurs in nearly all patients with End Stage Renal Disease (ESRD). Annually there are over 450,000 individuals in the U.S. that require medication to control their phosphate levels.[1] Uncontrolled hyperphosphatemia is strongly associated with increased death and hospitalization for CKD patients on dialysis. Treatment of hyperphosphatemia is aimed at lowering serum phosphate levels via two means: (1) restricting dietary phosphorus intake; and (2) using, on a daily basis, and with each meal, oral phosphate binding drugs that facilitate fecal elimination of dietary phosphate rather than its absorption from the gastrointestinal tract into the bloodstream.
[1] Flythe JE. Dialysis-Past, Present, and Future: A Kidney360 Perspectives Series. Kidney360. 2023 May 1;4(5):567-568. doi: 10.34067/KID.0000000000000145.
About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive?s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com.
Forward-looking statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern Unicycive's expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive's current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; Unicycive's clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; Unicycive's dependence on third parties for manufacturing; the possibility that FDA may require inspection of any vendor prior to approval, which could delay or prevent approval of its NDA; the risk that the inspection of the original or new third-party manufacturing vendor may not occur within a timeframe that benefits its regulatory timeline, or may result in adverse findings; risks related to business interruptions, which could seriously harm its financial condition and increase its costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; market acceptance of its products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled 'Risk Factors' in Unicycive's Annual Report on Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Investor Contacts: Kevin Gardner, LifeSci Advisors, [email protected]
Media Contact: Unicycive Therapeutics, [email protected]
ImmunoForge to Showcase Proprietary Platform Technologies and Next-Generation Oncology and Phase 2 Clinical Pipelines at BIO-Europe 2026PR NewswireSEOUL, South Ko
Investors might want to bet on Oddity Tech (ODD - Free Report) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.
A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.
Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts, since these are mostly driven by subjective factors that are hard to see and measure in real time. In these situations, the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near-term stock price movements.
Therefore, the Zacks rating upgrade for Oddity Tech basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.
Most Powerful Force Impacting Stock PricesThe change in a company's future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. The influence of institutional investors has a partial contribution to this relationship, as these big professionals use earnings and earnings estimates to calculate the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their bulk investment action then leads to price movement for the stock.
Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Oddity Tech imply an improvement in the company's underlying business. Investors should show their appreciation for this improving business trend by pushing the stock higher.
Harnessing the Power of Earnings Estimate RevisionsEmpirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, so it could be truly rewarding if such revisions are tracked for making an investment decision. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .
Earnings Estimate Revisions for Oddity TechFor the fiscal year ending December 2026, this online retailer of cosmetics and beauty products is expected to earn $0.44 per share, which is unchanged compared with the year-ago reported number.
Analysts have been steadily raising their estimates for Oddity Tech. Over the past three months, the Zacks Consensus Estimate for the company has increased 55.5%.
Bottom LineUnlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.
You can learn more about the Zacks Rank here >>>
The upgrade of Oddity Tech to a Zacks Rank #1 positions it in the top 5% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:
CarMax, Inc. (KMX - Free Report) : This automotive retail company has seen the Zacks Consensus Estimate for its current year earnings increasing 10.3% over the last 60 days.
American Coastal Insurance Corporation (ACIC - Free Report) : This property and casualty insurance company has seen the Zacks Consensus Estimate for its current year earnings increasing 35.7% over the last 60 days.
BeOne Medicines AG (ONC - Free Report) : This oncology company has seen the Zacks Consensus Estimate for its current year earnings increasing 15.2% over the last 60 days.
Oddity Tech Ltd. (ODD - Free Report) : This consumer tech company has seen the Zacks Consensus Estimate for its current year earnings increasing 633.3% over the last 60 days.
Western Midstream Partners, LP (WES - Free Report) : This midstream energy company has seen the Zacks Consensus Estimate for its current year earnings increasing 2.2% over the last 60 days.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
NANJING, China, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that opamtistomig (LBL-024), the Company’s proprietary PD‑L1/4‑1BB bispecific antibody, has been granted Orphan Drug Designation (ODD) by Japan’s Ministry of Health, Labour and Welfare (MHLW) for the treatment of extrapulmonary neuroendocrine carcinoma (EP-NEC). This is the third Orphan Drug Designation for opamtistomig, following designations in the U.S. Food and Drug Administration (FDA) and the European Commission (EC), marking a further expansion of its global regulatory recognition into a strategically important Asian market.
The designation provides opamtistomig with access to a range of regulatory and development incentives in Japan, which may include:
Financial support and subsidies for clinical development.Regulatory consultation and advice from Japan’s Ministry of Health, Labour and Welfare (MHLW) and other relevant authorities.Potential access to priority consultation and expedited review pathways, as applicable.Reduction or exemption of certain application and examination fees, andAn extended re‑examination period following marketing authorization. These incentives are expected to facilitate and potentially accelerate the clinical development, regulatory submission, and commercialization of opamtistomig in Japan, particularly for EP-NEC and other high-potential indications.
Japan is one of the world’s major pharmaceutical markets, with a market size of over $73 billion in 2025, of which the immuno‑oncology segment accounted for over $8 billion, ranking behind only the United States, China, and Europe. By securing orphan drug designation in this strategic market, opamtistomig not only represents a breakthrough for the EP‑NEC indication but also establishes priority consultation and accelerated review pathways within Japan’s regulatory framework, paving the way for the subsequent development and registration of opamtistomig for other tumor indications in Japan.
Since October 2024, opamtistomig has received Breakthrough Therapy Designation from the National Medical Products Administration (NMPA) of China, Orphan Drug Designation and Fast Track designation from the U.S. FDA, and Orphan Drug Designation from the European Commission. In July 2026, its New Drug Application (NDA) was granted Priority Review by the NMPA. In August 2026, NDA submitted to NMPA and now under technical review. To date, opamtistomig has demonstrated promising and durable efficacy signals across seven tumor types, including EP‑NEC (first‑line and post‑line), non‑small cell lung cancer (NSCLC), small cell lung cancer (SCLC), biliary tract cancer (BTC), hepatocellular carcinoma (HCC), esophageal squamous cell carcinoma (ESCC), and ovarian cancer (OC).
Clinical results from multiple studies of opamtistomig in EP‑NEC, NSCLC, and BTC have been presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, the World Conference on Lung Cancer (WCLC), and the European Society for Medical Oncology (ESMO) Annual Congress. The clinical data and innovative value of opamtistomig have been widely recognized, further validating opamtistomig as an “IO 2.0” backbone therapy with survival benefit across immunologically ‘cold tumors’ and a broad range of indications.
Executive Commentary
Dr. Charles Cai, Chief Medical Officer of Leads Biolabs, commented: “The orphan drug designation in Japan represents an important milestone in the global development of opamtistomig and further strengthens its regulatory recognition across the four key markets of China, the United States, Europe, and Japan. It underscores the innovative value and global development potential of opamtistomig, particularly in EP-NEC, a tumor type with substantial unmet medical needs. We look forward to leveraging the regulatory incentives associated with this designation to accelerate the development and registration of opamtistomig in Japan, while advancing additional high-potential indications and bringing this innovative therapy to more patients in Japan and around the world.”
About Opamtistomig
Opamtistomig (LBL-024) is emerging as a next-generation pan-cancer backbone therapy with potential overall survival (OS) benefit that simultaneously targets PD-L1 and the co-stimulatory receptor 4-1BB. Currently, opamtistomig is being evaluated in 14 indications, including one pivotal single-arm registrational study, one confirmatory Phase III study, and nine proof-of-concept studies, covering major indications such as NSCLC and multiple cold tumors. To date, opamtistomig has demonstrated robust antitumor activity across seven tumor types—extrapulmonary neuroendocrine carcinoma (EP-NEC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), biliary tract cancer (BTC), hepatocellular carcinoma (HCC), esophageal squamous cell carcinoma (ESCC), and ovarian cancer (OC)—highlighting its clinical value and broad therapeutic promise.
Developed using Leads Biolabs’ proprietary X-Body bispecific platform, opamtistomig is designed to simultaneously block PD-1/PD-L1 immune suppression and conditionally activate 4-1BB, an agonist pathway, resulting in a potent and synergistic anti-tumor immune response. It has a safety profile comparable to PD-1/PD-L1 inhibitors and demonstrates broader-spectrum anti-cancer potential. Mechanistically, 4-1BB agonism can reactivate exhausted T cells and promote robust T-cell proliferation, offering significant promise for PD-1/PD-L1–resistant or immunologically “cold” tumors and potentially offering durable survival benefits.
Recognizing its clinical potential, opamtistomig received Breakthrough Therapy Designation (BTD) from China's National Medical Products Administration (NMPA) in October 2024, and Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) in November 2024. Additionally, in January 2026, opamtistomig was granted Fast Track Designation (FTD) by the FDA and ODD by the European Commission, further underscoring its potential to address unmet medical needs in this patient population. In July 2026, its New Drug Application (NDA) was granted priority review designation by the NMPA, followed by NDA acceptance in August 2026, positioning opamtistomig as a potential world's first approved 4-1BB-targeting antibody, the first approved agonist antibody, and the first approved treatment for EP-NEC.
About Leads Biolabs
Founded in 2012, Leads Biolabs is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies to address underserved medical needs in oncology, autoimmune, and other severe diseases both in China and globally.
Leads Biolabs is a front-runner in next-generation immuno-oncology treatments with a differentiated pipeline of 15 innovative drug candidates, including five clinical-stage drug candidates and one registration-stage asset.
The Company adopts a science-driven R&D approach and has successfully established comprehensive R&D capabilities spanning antibody discovery and engineering, in vivo and in vitro efficacy evaluation, as well as druggability assessment. It has also developed multiple proprietary technology platforms, including LeadsBody (a CD3 T-cell engager platform), X-body (a 4-1BB engager platform), TOPiKinectics (an ADC platform) and ImBiTDC (a TDC platform), which serve as the cornerstone for its continued innovation and have been validated by the clinical outcomes of its bispecific antibody portfolios.
Leads Biolabs has established integrated capabilities across early discovery, translational medicine, clinical development, CMC and business development. The innovative nature and competitive strengths of its drug candidates, coupled with its global perspectives, proactive strategy, and efficient clinical validation, have made it an attractive partner for leading industry players and investment institutions. For more information, please visit https://en.leadsbiolabs.com/
On September 23, 2026, ODDITY Tech Ltd ODD shares fell 5.1% to $17.83, reflecting a significant drop in price performance over the last year, with a 52-week range between $9.25 and $63.56. The stock has struggled notably this year, down 55.6% year-to-date and 70.8% over the past year.
GF Value™ verdict: Current price of $17.83 vs GF Value™ of $49.24, indicating a 63.8% undervaluation.GF Score™: 71/100, classified as Above Average.Most notable signal: Insider activity shows $3.0M in sales over the past 12 months with no buying.Is ODD Overvalued or Undervalued?Given the current price of $17.83 and the GF Value™ estimate of $49.24, ODDITY Tech Ltd appears significantly undervalued at a margin of 63.8%. However, it's essential to interpret this information cautiously. GF Value™ represents GuruFocus' proprietary assessment of a stock's intrinsic value based on historical trading multiples, past business growth, and future performance estimates. In this instance, the high GF Value™ indicates potential, but investors should be wary as the company is unprofitable and cash-flow negative, leading to the GF Valuation label of "Possible Value Trap." This warning suggests that while the stock price may seem attractive, the underlying business performance raises concerns that could hinder future price appreciation.
Investors must consider the risks associated with investing in a loss-making company like ODDITY Tech Ltd. The lack of profitability can lead to volatility and uncertainty, making it crucial to analyze other valuation metrics before making investment decisions.
How Does ODD's Valuation Compare to Its History?MetricCurrentHistoricalP/E (TTM)74.9x29.4xForward P/E15.2xN/ACurrently, ODD's P/E (TTM) of 74.9x is considerably above its 5-year median of 29.4x, indicating that the stock is trading at a premium compared to its historical valuation. This high P/E ratio aligns with the GF Value™ assessment, suggesting that the stock may be overvalued based on earnings. Given that the current P/E is 155% above its historical median, this reinforces the notion that earnings-based valuation methods may not be applicable for a company that is not generating profits.
What Does ODD's GF Score™ Tell Us?The GF Score™ is an overall rating that assesses a stock’s potential based on various factors, including financial strength, profitability, growth, valuation, and momentum. ODD's GF Score™ of 71/100 indicates it is performing above average relative to its peers. The strongest sub-rank is in profitability, where it holds a score of 8/10, reflecting its ability to generate profits relative to its peers. However, it ranks weakest in valuation, at 2/10, indicating concerns over its current price relative to its earnings and growth potential.
MetricRatingGF Score™71Financial Strength4/10Profitability8/10Growth7/10Valuation2/10Momentum4/10Overall, the scores reflect a mixed outlook for ODDITY Tech Ltd. While the company shows strong potential in profitability and growth, its financial strength and valuation metrics raise substantial red flags. This discrepancy between strong profitability and weak valuation suggests that while there may be opportunities for growth, the current market perception may not align with the underlying business fundamentals.
What Are Gurus and Insiders Doing with ODD?Currently, three gurus hold positions in ODDITY Tech Ltd, with two of them adding to their stakes and three trimming their positions in recent quarters. This mixed activity indicates a cautious outlook among institutional investors. Notably, insider activity reveals that insiders sold $3.0M worth of shares over the past 12 months without any buying, which often signals a lack of confidence in the company's near-term prospects.
This pattern of insider selling can suggest a lack of faith in the company's ability to recover or generate profits in the near future, further complicating the investment narrative for potential investors. The combination of guru ownership trends and insider selling can serve as critical signals for assessing the company's future performance.
What This Means for InvestorsIn conclusion, ODDITY Tech Ltd appears to be undervalued based on its GF Value™ of $49.24 compared to its current price of $17.83. However, given the company's unprofitability and cash-flow negative status, caution is advised. The stock may represent an opportunity if the business can turn around its performance, but the risks associated with its current financial situation cannot be overlooked. For further details, you can explore the ODDITY Tech Ltd ODD stock page for more insights.
Frequently Asked QuestionsWhat is ODD's GF Score™?
ODD's GF Score™ is 71/100, indicating that it is performing above average compared to its peers, suggesting potential for growth but also highlighting some concerns.
Is ODD overvalued or undervalued?
According to the GF Value™, ODD is currently undervalued, with a significant margin suggesting potential upside, yet caution is warranted due to ongoing unprofitability.
What is ODD's P/E ratio?
ODD's P/E (TTM) stands at 74.9x, which is significantly higher than its 5-year median of 29.4x, indicating that the stock is trading at a premium relative to its historical valuation.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Disclosures I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.
Oddity Tech (ODD - Free Report) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving.
Analysts' growing optimism on the earnings prospects of this online retailer of cosmetics and beauty products is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Our stock rating tool -- the Zacks Rank -- has this insight at its core.
The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.
Consensus earnings estimates for the next quarter and full year have moved considerably higher for Oddity Tech, as there has been strong agreement among the covering analysts in raising estimates.
The chart below shows the evolution of forward 12-month Zacks Consensus EPS estimate:
12 Month EPS
Current-Quarter Estimate RevisionsThe earnings estimate of $0.34 per share for the current quarter represents a change of -15.0% from the number reported a year ago.
The Zacks Consensus Estimate for Oddity Tech has increased 440% over the last 30 days, as one estimate has gone higher compared to no negative revisions.
Current-Year Estimate RevisionsFor the full year, the company is expected to earn $0.49 per share, representing a year-over-year change of -77.8%.
There has been an encouraging trend in estimate revisions for the current year as well. Over the past month, two estimates have moved up for Oddity Tech versus no negative revisions. This has pushed the consensus estimate 72.73% higher.
Favorable Zacks RankThe promising estimate revisions have helped Oddity Tech earn a Zacks Rank #2 (Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500.
Bottom LineWhile strong estimate revisions for Oddity Tech have attracted decent investments and pushed the stock 55.7% higher over the past four weeks, further upside may still be left in the stock. So, you may consider adding it to your portfolio right away.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Shares of Oddity Tech (ODD +26.53%) absolutely skyrocketed on Wednesday. The Israel-based maker of data-driven beauty products reported earnings early this morning, narrowly exceeding Wall Street's estimates. The stock closed 26.5% higher, having soared as much as 41.6% just after the market open.
Image source: Getty Images.
A 25% sales drop and a 26.5% stock pop Those jumps are not typos or miscalculations, but I was also serious about the narrow surprises. Oddity Tech's Q2 2026 sales fell 25% year over year, landing at $181 million. Earnings per share dropped from $0.92 to $0.20. The average analyst targets were $176.5 million and $0.19 per share, respectively. Furthermore, management offered its first revenue guidance for the 2026 fiscal year, targeting a year-over-year drop of approximately 19%.
Oddity Tech's mellow report sparked an odd market reaction. Investors focused on solid results for the SpoiledChild anti-aging products and the Methodiq telehealth service, while the Il Makiage makeup division is working through algorithm shifts with a key marketing partner.
Premium Feature
Moneyball Superscore
61/100
Today's Change
(
26.53
%) $
3.46
Current Price
$
16.48
The bull case and the catch To be fair, the bright spots were brilliant. The SpoiledChild brand is on track to reach nearly $350 million in total sales in 2026, 35% above the previous year. The Methodiq line is just a few months old, but it is tracking ahead of SpoiledChild's early results. And the Il Makiage issues are slowly resolving, setting the company up for stronger results in 2027 and beyond.
But this is an odd duck on Wall Street. Oddity Tech sells cosmetics the way a software company sells software, and it owns a Boston biotech lab to make the ingredients. And it runs sales the way Lemonade sells insurance: through an online quiz to define your beauty needs. There are also echoes of Stitch Fix's try-before-you-buy tactics.
Results are lumpy, the stock is volatile, and some 23% of its shares are sold short. And even after Wednesday's 26.5% gain, it's still down 74% over the last 52 weeks. This jump is more of a rebound than a victory march.
Oddity Tech is an incredibly interesting business, but it runs a fragile marketing strategy. Every brand, including the healthy ones, depends on the same paid social funnel, and one algorithm change took first orders down by 40%. I don't mind watching this turnaround story from the sidelines.
Anders Bylund has positions in Lemonade. The Motley Fool has positions in and recommends Lemonade. The Motley Fool recommends Stitch Fix. The Motley Fool has a disclosure policy.
ODDITY (NASDAQ:ODD) shares jumped 14% on Wednesday after the company posted second-quarter results that topped Wall Street estimates and issued a stronger-than-expected full-year profit outlook.
The consumer tech company reported revenue of $181 million for the quarter, beating estimates of $178 million but down 25% from a year earlier. Adjusted earnings per share came in at $0.20, ahead of the $0.16 estimate, while adjusted EBITDA reached $13 million, more than the $8.8 million analysts had projected.
For fiscal 2026, ODDITY guided adjusted EBITDA of $30 million to $32 million, well above the $10.7 million estimate, with revenue expected to decline 19% year-over-year. For the third quarter, the company forecast adjusted EBITDA of $18 million to $20 million against estimates of $6.3 million, with revenue seen down 5% from a year earlier.
Gross margin was 68.7%, down 360 basis points from a year ago. Net income for the quarter was $13 million, and the company held $561 million in cash, cash equivalents and investments.
"We made progress during the quarter, including strong results for both SpoiledChild and METHODIQ," said Oran Holtzman, ODDITY co-founder and CEO. "We remain hopeful that IL MAKIAGE is on track to achieve normalization and we continue to work in close partnership with our largest advertising partner to solve the technical issue."
ODDITY is a consumer tech company that uses AI and data science to build digital-first beauty and wellness brands, including IL MAKIAGE, SpoiledChild and METHODIQ, serving over 70 million users.
No Investment Advice
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
Oddity Tech (ODD - Free Report) came out with quarterly earnings of $0.2 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.92 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +66.67%. A quarter ago, it was expected that this online retailer of cosmetics and beauty products would post a loss of $0.04 per share when it actually produced a loss of $0.17, delivering a surprise of -325%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Oddity Tech, which belongs to the Zacks Internet - Software industry, posted revenues of $180.52 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 3.27%. This compares to year-ago revenues of $241.14 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Oddity Tech shares have lost about 67.6% since the beginning of the year versus the S&P 500's gain of 12.1%.
What's Next for Oddity Tech?While Oddity Tech has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Oddity Tech was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.10 on $118.35 million in revenues for the coming quarter and $0.06 on $619.4 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Internet - Software is currently in the top 35% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Penguin Solutions, Inc. (PENG - Free Report) , has yet to report results for the quarter ended August 2026.
This company is expected to post quarterly earnings of $0.75 per share in its upcoming report, which represents a year-over-year change of +74.4%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Penguin Solutions, Inc.'s revenues are expected to be $512.5 million, up 51.7% from the year-ago quarter.
It's Not Too Late to Jump on These Under-the-Radar Momentum PlaysODDITY Tech NASDAQ: ODD reported second-quarter 2026 net revenue of $181 million, down 25% from a year earlier, as its IL MAKIAGE brand continued to face higher customer-acquisition costs tied to an advertising-account dislocation with its largest ad partner.
Management said the quarterly revenue result came in at the favorable end of its prior guidance range for a 25% to 30% decline. Adjusted EBITDA was $13 million, above the company’s outlook of $8 million to $10 million, while adjusted diluted earnings per share totaled $0.20.
Get ODDITY Tech alerts:
Oddity Tech's AI-Powered Debut Sparks Optimism For '23 IPO MarketCo-founder and CEO Oran Holtzman said the company remains focused on resolving the issue affecting IL MAKIAGE’s ability to reach intended audiences through its main advertising partner. He said ODDITY and the advertising partner are conducting intensive testing and that the company believes the issue is technical and related to “audience drift” in the partner’s algorithm rather than underlying brand demand.
“Once it’s behind us, we are back to growth,” Holtzman said, adding that IL MAKIAGE has a pipeline of products that the company intends to support once customer-acquisition costs normalize.
IL MAKIAGE Pressure Weighs on Sales and Margins Global CFO Lindsay Drucker Mann said IL MAKIAGE’s advertising disruption affected first-order revenue most heavily, while also reducing repeat purchases tied to advertising activity. Companywide net revenue from first orders declined about 40% year over year in the second quarter, driven by IL MAKIAGE, while repeat-order revenue fell about 20%.
Average order value declined approximately 8% from the prior-year period. Drucker Mann attributed the decline largely to lower IL MAKIAGE average order values, reflecting fewer first orders, which typically carry higher order values than repeat purchases, as well as a product-mix shift away from IL MAKIAGE skin products.
Gross margin fell to 68.7% from 72.3% a year earlier, a decline of approximately 360 basis points. The company cited lower average order values as a factor. Drucker Mann said ODDITY does not view the margin pressure as structural, noting that its longer-term gross-margin expectation remains in the high-60% range and that improved acquisition conditions should allow the company to resume optimizing for average order value.
Holtzman said the company is also expanding its efforts across distribution and advertising channels to make the business more resilient, though he did not announce specific initiatives. He said maintaining a substantial direct-to-consumer business remains important because of the customer data it provides.
SpoiledChild and METHODIQ Provide Growth Areas While IL MAKIAGE faced pressure, management highlighted continued momentum at SpoiledChild and early progress from the recently launched METHODIQ brand.
SpoiledChild is expected to grow at least 35% in 2026 and approach $350 million in net revenue, according to Holtzman. He said the wellness brand continued to generate strong customer cohort metrics, including average order value and repeat purchasing. Twelve-month net-revenue repeat rates at SpoiledChild are above 100%, management said.
The company said SpoiledChild has been affected by the same advertising-algorithm issue, but to a lesser degree than IL MAKIAGE. ODDITY increased acquisition spending behind SpoiledChild during the quarter, citing attractive expected 12-month contribution margins. Holtzman said the company plans to continue international expansion for the brand and has more than eight products and categories planned for next year.
METHODIQ, which launched several months ago, is expected to generate more first-year revenue than SpoiledChild did in its first year, according to management. The medical-grade brand launched with 30 products spanning non-prescription offerings, prescription products and personalized treatment protocols.
Holtzman pointed to hyperpigmentation as an early area of traction for METHODIQ. The brand uses computer vision to assess dark spots and uneven skin tone, with the resulting data provided to a healthcare provider that can issue a personalized treatment plan. He said one of METHODIQ’s products, Melanex 509, uses ODDITY LABS’ patented molecule combination called ODDL1007.
The company also plans to expand METHODIQ into additional categories in 2027. Holtzman said a category of particular interest is longevity and metabolic health, where the company intends to offer legally available prescription injectable and peptide therapies.
Outlook Calls for Sequential Improvement For the third quarter, ODDITY expects net revenue to decline approximately 5% year over year, representing a meaningful improvement from the first half of 2026. The company expects adjusted EBITDA of $18 million to $20 million.
For the full year, ODDITY forecast a net-revenue decline of approximately 19% and adjusted EBITDA between $30 million and $32 million. Drucker Mann said the company expects stronger repeat revenue in the second half but is maintaining a conservative fourth-quarter outlook because it has not yet determined how much advertising spending will be directed toward testing versus revenue generation.
The company ended the quarter with $561 million in cash equivalents and investments, while its $350 million in credit facilities remained undrawn. During the quarter, ODDITY repurchased 5.6 million shares for $80 million, bringing year-to-date repurchases to 11.7 million shares for $163 million. The company said those repurchases reduced ordinary shares outstanding by approximately 20%, with about $87 million remaining under its $200 million repurchase authorization.
ODDITY also repurchased $50 million face value of its zero-coupon June 2030 exchangeable notes for $35 million during June. Management said it plans to remain opportunistic in managing its capital structure.
About ODDITY Tech (NASDAQ:ODD)Oddity Tech Ltd. operates as a consumer tech company that builds digital-first brands for the beauty and wellness industries in the United States and internationally. It serves consumers worldwide through its AI-driven online platform, which uses data science, machine learning, and computer vision capabilities to identify consumer needs, and develop solutions in the form of beauty and wellness products. The company sells beauty, hair, and skin products under the IL MAKIAGE and SpoiledChild brands.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in ODDITY Tech Right Now?Before you consider ODDITY Tech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ODDITY Tech wasn't on the list.
While ODDITY Tech currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Second quarter net revenue of $181 million, down approximately 25% year-over-yearSecond quarter adjusted EBITDA of $13 millionSecond quarter net income of $13 million and second quarter adjusted net income of $11 millionStrong liquidity position including cash, cash equivalents and investments of $561 million, and aggregate credit facilities of $350 million which remain undrawn NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- ODDITY Tech Ltd. (NASDAQ: ODD) today announced its financial results for the second quarter ended June 30, 2026.
“We made progress during the quarter, including strong results for both SpoiledChild and METHODIQ,” said Oran Holtzman, ODDITY co-founder and CEO. “We remain hopeful that IL MAKIAGE is on track to achieve normalization and we continue to work in close partnership with our largest advertising partner to solve the technical issue.”
ODDITY achieved key objectives during the second quarter, including:
Double-digit revenue growth for SpoiledChild during the second quarter. SpoiledChild is on track to grow at least 35% compared to 2025 and approach $350 million of net revenue in 2026.Strong early results for METHODIQ, which we now expect to deliver first-year net revenue ahead of SpoiledChild’s first year.Ongoing development and expansion of the ODDITY Labs molecule discovery platform.Enhancing our capital structure, including repurchasing $80 million of our Class A ordinary shares and retiring $50 million of our zero coupon 2030 exchangeable notes, while maintaining a strong liquidity position. “So far in the third quarter, we are seeing an improved year-over-year net revenue trend, driven by growth at SpoiledChild and METHODIQ and a moderating impact from the IL MAKIAGE account dislocation,” said Lindsay Drucker Mann, ODDITY Global CFO. “As a result, we now expect third quarter net revenue to decline approximately 5% year-over-year, a meaningful sequential improvement from the first half.”
Update on IL MAKIAGE Account Dislocation
ODDITY continues to work closely with its largest advertising partner to solve the advertising algorithm dislocation at IL MAKIAGE. Since its last earnings call, ODDITY has implemented various tests and strategies to address signal distortion and retrain the algorithm. ODDITY continues to believe the dislocation is technical in nature and solvable, and is encouraged by the progress it is making toward normalization.
Share Buybacks
ODDITY repurchased approximately 5.6 million Class A ordinary shares during the second quarter for approximately $80 million under the $200 million share buyback plan authorized in March 2026 (the “2026 Buyback Plan”). On a year-to-date basis, ODDITY has repurchased approximately 11.7 million Class A ordinary shares for approximately $163 million, including approximately $50 million of repurchases completed before the adoption of the 2026 Buyback Plan under ODDITY’s prior share buyback authorization, reducing total ordinary shares outstanding by approximately 20%. Approximately $87 million remains under the 2026 Buyback Plan, subject to market conditions and legal and regulatory constraints.
Exchangeable Note Repurchase
In June 2026, ODDITY repurchased and retired $50 million aggregate principal amount of its 0% exchangeable notes due 2030 for approximately $35 million, leaving approximately $550 million aggregate principal amount outstanding.
Second Quarter Fiscal 2026 Financial Highlights:
Results for the second quarter ended June 30, 2026 are presented below in comparison to the second quarter ended June 30, 2025.
Net revenue was $181 million compared to $241 million in the second quarter of 2025, a decrease of 25%.Gross profit was $124 million compared to $174 million in the second quarter of 2025; gross margin was 68.7% compared to 72.3%.Net income was $13 million compared to $49 million in the second quarter of 2025.Adjusted net income was $11 million compared to $57 million in the second quarter of 2025.Adjusted EBITDA was $13 million compared to $70 million in the second quarter of 2025.Diluted earnings per share was $0.24 compared to $0.79 in the second quarter of 2025.Adjusted diluted earnings per share was $0.20 compared to $0.92 in the second quarter of 2025.Cash, cash equivalents, and investments were $561 million as of June 30, 2026. Financial results have been rounded to the nearest million, unless indicated otherwise.
The table below sets forth our actual results for the three months ended June 30, 2026 and the low and high end of our guidance range regarding our results for the second quarter of 2026 as issued on June 2, 2026.
Three months ended June 30, 2026 Actual
ResultsGuidance
Low EndGuidance
High EndNet Revenue-25%-30%-25%Adjusted EBITDA$13 million$8 million$10 million
Financial Outlook:
ODDITY is providing the following guidance for the third quarter ending September 30, 2026:
Net revenue to decline by approximately 5% year-over-yearAdjusted EBITDA between $18 million and $20 million ODDITY is providing the following guidance for the full year ending December 31, 2026:
Net revenue to decline by approximately 19% year-over-yearAdjusted EBITDA between $30 million and $32 million Adjusted EBITDA, Adjusted net income, and Adjusted diluted earnings per share are non-GAAP financial measures. Please see the sections titled “Non-GAAP Financial Measures” and “Reconciliation of GAAP to Non-GAAP Measures” below for more information regarding ODDITY’s use of non-GAAP financial measures and reconciliations to the most directly comparable GAAP measures. ODDITY has not provided a quantitative reconciliation of its Adjusted EBITDA outlook to the corresponding net income measure because the quantification of certain items included in the calculation of GAAP net income cannot be calculated or predicted at this time without unreasonable efforts. ODDITY is unable to address the probable significance of the unavailable reconciling items, which could have a potentially unpredictable, and potentially significant, impact on its future GAAP financial results.
The financial outlook figures presented above are forward-looking statements that are subject to a variety of assumptions and estimates. Actual results may differ materially from ODDITY’s financial outlook as a result of, among other things, the factors described under “Forward-Looking Statements” below.
Conference Call Details:
A conference call to discuss ODDITY’s Q2 2026 financial and business results and outlook is scheduled for today, September 9, 2026, at 8:30 a.m. ET. To participate, please dial 1-877-407-9208 (US) or 1-201-493-6784 (international). To access the call, please reference the company name and call title: ODDITY Second Quarter 2026 Earnings Call. A webcast of the call will be accessible on the Investors section of ODDITY’s website at https://investors.oddity.com. A recording will be available shortly after the conclusion of the call. To access the replay, please dial 1-844-512-2921 (US) or 1-412-317-6671 (international). The access code for the replay is 13761986. An archive of the webcast will be available on the Investors section of ODDITY’s website for seven days following the call.
Non-GAAP Financial Measures:
In addition to the GAAP financial measures set forth in this press release, ODDITY has included the following non-GAAP financial measures: Adjusted EBITDA, Adjusted net income, Adjusted diluted earnings per share, and free cash flow. ODDITY believes these non-GAAP financial measures provide useful supplemental information to management and investors to help evaluate ODDITY’s business, measure its performance, identify trends, prepare financial projections, and make business decisions.
ODDITY defines “Adjusted EBITDA” as net income (loss) before financial income, net, taxes on income, and depreciation and amortization as further adjusted to exclude share-based compensation expense and certain unusual or non-recurring items. ODDITY believes Adjusted EBITDA is useful for financial and operational decision-making and as a means to evaluate period-to-period comparisons. By excluding certain items that may not be indicative of its recurring core operating results, ODDITY believes that Adjusted EBITDA provides meaningful supplemental information regarding its performance. In addition, Adjusted EBITDA is widely used by investors and securities analysts to measure a company’s operating performance without regard to items such as depreciation and amortization, interest expense, and interest income, which can vary substantially from company to company depending on their financing and capital structures and the method by which their assets were acquired.
ODDITY defines “Adjusted net income” as net income (loss) adjusted for the impact of share-based compensation, certain unusual or non-recurring items, one-time tax gains/losses and the tax effect of non-GAAP adjustments. In addition, ODDITY defines “Adjusted diluted earnings per share” as Adjusted net income divided by diluted shares outstanding. ODDITY believes the presentations of Adjusted net income and Adjusted diluted earnings per share are useful because they are frequently used by analysts, investors and other interested parties to evaluate companies in our industry. Further, ODDITY believes these measures are helpful in highlighting trends in our operating results, because they exclude the impact of items that are outside the control of management or not reflective of our ongoing operations and performance.
ODDITY defines “free cash flow” as net cash (used in) provided by operating activities less purchase of property and equipment.
ODDITY’s non-GAAP financial measures should be considered in addition to, not as a substitute for or in isolation from, its financial results prepared in accordance with U.S. GAAP. Other companies, including companies in our industry, may calculate these measures differently or not at all, which reduces their usefulness as comparative measures.
Reconciliations of non-GAAP financial measures to the most directly comparable GAAP measures are included with the financial tables at the end of this release under the heading “Reconciliation of GAAP to Non-GAAP Measures.”
Forward-Looking Statements:
Certain statements in this press release may constitute “forward-looking” statements and information, within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995 that relate to our current expectations and views of future events. In some cases, these forward-looking statements can be identified by words or phrases such as “aim,” “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “goal,” “hope,” “intend,” “may,” “objective,” “plan,” “potential,” “predict,” “project,” “shall,” “should,” “target,” “will,” “seek,” or similar words. The absence of these words does not mean that a statement is not forward-looking. These forward-looking statements address various matters, including ODDITY’s business strategy, market opportunity, ability to deliver superior products and experiences, ability to remedy the dislocation in our customer acquisition costs, potential long-term success and ODDITY’s outlook for the third quarter of 2026 and the full year ending December 31, 2026. These forward-looking statements are subject to risks, uncertainties and assumptions, some of which are beyond our control. In addition, these forward-looking statements reflect our current views with respect to future events and are not a guarantee of future performance. Actual outcomes may differ materially from the information contained in the forward-looking statements as a result of a number of factors, including, without limitation, the following: our ability to maintain the value of our brands; our ability to anticipate and respond to market trends and changes in consumer preferences; our ability to cost-effectively attract new customers (including by responding effectively to changes to algorithm-based bidding systems on key advertising platforms), retain existing customers and maintain or increase sales to those customers; our ability to maintain a strong base of engaged customers and content creators; the loss of suppliers or shortages or disruptions in the supply of raw materials or finished products; our ability to accurately forecast customer demand, manage our inventory, and plan for future expenses; our future rate of growth; competition; the fluctuating cost of raw materials; the illegal distribution and sale by third parties of counterfeit versions of our products or the unauthorized diversion by third parties of our products; changes in, or disruptions to, our shipping arrangements; our ability to manage our growth effectively; a general economic downturn or sudden disruption in business conditions; our ability to successfully introduce and effectively market new brands, or develop and introduce new, innovative, and updated products; foreign currency fluctuations; product returns; our ability to execute on our business strategy; our ability to maintain a high level of customer satisfaction; our ability to comply with and adapt to changes in laws and regulatory requirements applicable to our business, including with respect to regulation of the internet and e-commerce, evolving AI-technology related laws, tax laws, the anti-corruption, trade compliance, anti-money laundering, and terror finance and economic sanctions laws and regulations, consumer protection laws, and data privacy and security laws; failure of our products to comply with quality standards and risks related to product liability claims; trade restrictions; existing and potential tariffs; any data breach or other security incident of our information technology systems, or those of our third-party service providers or cyberattacks; risks related to online transactions and payment methods; any failure to obtain, maintain, protect, defend, or enforce our intellectual property rights; conditions in Israel and the Middle East generally, including as a result of geopolitical conflict; the concentration of our voting power as a result of our dual class structure; our status as a foreign private issuer; and other risk factors set forth in the section titled “Risk Factors” in our Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 17, 2026, and other documents filed with or furnished to the SEC. These statements reflect management’s current expectations regarding future events and operating performance and speak only as of the date of this press release. You should not put undue reliance on any forward-looking statements. Except as required by applicable law, we undertake no obligation to update or revise publicly any forward-looking statements.
About ODDITY:
ODDITY is a consumer tech company that builds and scales digital-first brands to disrupt the offline-dominated beauty and wellness industries. The company serves over 70 million users with its AI-driven online platform, deploying data science to identify consumer needs, and developing solutions in the form of beauty and wellness products. ODDITY owns IL MAKIAGE, SpoiledChild, and METHODIQ. The company operates with business headquarters in New York City, an R&D center in Tel Aviv, Israel, and a biotechnology lab in Boston.
ODDITY TECH LTD.CONSOLIDATED STATEMENTS OF INCOMEU.S. dollar in thousands (except per share data)
Three months ended
June 30, Six months ended
June 30, 2026
2025
2026
2025
Unaudited UnauditedNet revenue $180,517 $241,140 $378,457 $509,216 Cost of revenue 56,571 66,788 116,541 134,016 Gross profit 123,946 174,352 261,916 375,200 Selling, general and administrative 125,206 117,258 288,666 275,441 Operating (loss) income (1,260) 57,094 (26,750) 99,759 Financial (income), net (16,533) (2,493) (21,839) (5,140) Income (loss) before taxes on income 15,273 59,587 (4,911) 104,899 Taxes on income 2,383 10,302 3,560 17,783 Net income (loss) $12,890 $49,285 $(8,471) $87,116 Weighted-average number of shares – basic (thousands) 47,683 56,822 51,974 56,413 Weighted-average number of shares – diluted (thousands) 54,084 62,335 51,974 61,329 Earnings (loss) per share attributable to Class A and Class B Ordinary shareholders: Basic $0.27 $0.87 $(0.16) $1.54 Diluted $0.24 $0.79 $(0.16) $1.42 ODDITY TECH LTD.CONSOLIDATED BALANCE SHEETSU.S. dollar in thousands
June 30,
December 31,
2026
2025
(Unaudited)
(Audited)
ASSETS CURRENT ASSETS: Cash and cash equivalents $167,274 $402,209 Marketable securities 25,880 11,170 Trade receivables 12,129 16,902 Inventories 152,170 135,181 Prepaid expenses and other current assets 33,218 36,336 Total current assets 390,671 601,798 LONG-TERM ASSETS: Marketable securities 368,008 362,571 Property, plant and equipment, net 10,044 10,864 Deferred tax asset, net 28,811 27,693 Intangible assets, net 48,462 43,582 Goodwill 64,904 64,904 Operating lease right-of-use assets 19,918 22,311 Other assets 4,305 4,069 Total long-term assets 544,452 535,994 Total assets $935,123 $1,137,792 ODDITY TECH LTD.CONSOLIDATED BALANCE SHEETSU.S. dollar in thousands
June 30, December 31,
2026
2025
(Unaudited) (Audited)
LIABILITIES AND SHAREHOLDERS’ EQUITY CURRENT LIABILITIES: Trade payables $63,076 $75,957 Other accounts payable and accrued expenses 44,347 32,869 Operating lease liabilities, current 5,764 6,002 Total current liabilities 113,187 114,828 LONG-TERM LIABILITIES: Operating lease liabilities, non-current 16,231 17,463 Exchangeable Note 537,246 584,368 Other long-term liabilities 25,187 24,638 Total liabilities 691,851 741,297 SHAREHOLDERS’ EQUITY: Class A Ordinary shares 11 15 Class B Ordinary shares 3 3 Additional paid-in capital (65,340) 77,571 Accumulated other comprehensive income 3,055 4,892 Retained earnings 305,543 314,014 Total shareholders’ equity 243,272 396,495 Total liabilities and shareholders’ equity $935,123 $1,137,792 ODDITY TECH LTD.
CONSOLIDATED STATEMENTS OF CASH FLOWS
U.S. dollar in thousands Six months ended
June 30, 2026
2025
(Unaudited)Cash flows from operating activities: Net (loss) income $(8,471) $87,116 Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities: Depreciation and amortization 7,501 5,308 Share-based compensation 17,887 16,853 Deferred income taxes (718) (1,109) Amortization of debt issuance costs 1,708 - Gain on repurchase of 0% exchangeable senior notes due 2030 ("exchangeable notes") (13,539) - Change in trade receivables 4,773 (1,578) Change in prepaid expenses and other receivables 2,827 (422) Change in inventories (16,989) 5,576 Change in trade payables (12,881) (7,315) Change in other accounts payable and accrued expenses 13,192 (3,191) Change in operating lease right-of-use assets 4,018 3,911 Change in operating lease liability (3,094) (2,872) Other (2,159) (893) Net cash (used in) provided by operating activities $(5,945) $101,384 Cash flows from investing activities: Purchase of property and equipment (1,559) (1,951) Capitalization of software development costs and investment in other intangible assets (8,053) (3,290) Investment in marketable securities, net (21,475) (81,224) Maturities in short-term deposits - 47,000 Other investing activities - (151) Net cash used in investing activities (31,087) (39,616) Cash flows from financing activities: Proceeds from issuance of exchangeable notes, net of issuance costs - 583,500 Repurchase of exchangeable notes (35,125) - Purchase of capped calls - (50,592) Proceeds from exercise of options 27 11,444 Repurchase and retirement of Class A ordinary shares (162,778) - Net cash (used in) provided by financing activities (197,876) 544,352 Effect of exchange rate fluctuations on cash and cash equivalents (75) 432 Net (decrease) increase in cash, cash equivalents and restricted cash (234,983) 606,552 Cash, cash equivalents and restricted cash at the beginning of the period 402,279 50,347 Cash, cash equivalents and restricted cash at the end of the period $167,296 $656,899 ODDITY TECH LTD.Reconciliation of GAAP to Non-GAAP MeasuresU.S. dollar in thousands (except per share data) Three months ended
June 30,
Six months ended
June 30,
2026
2025
2026
2025
(Unaudited) (Unaudited)Reconciliation of Net Income (Loss) and Adjusted EBITDA Net income (loss) $12,890 $49,285 $(8,471) $87,116 Financial (income), net (16,533) (2,493) (21,839) (5,140) Taxes on income 2,383 10,302 3,560 17,783 Depreciation and amortization 3,232 2,653 7,501 5,308 Share-based compensation 9,786 9,769 17,887 16,853 Other adjustments1 1,115 - 7,199 - Adjusted EBITDA $12,873 $69,516 $5,837 $121,920 Reconciliation of Net Income (Loss) and Adjusted Net Income Net income (loss) $12,890 $49,285 $(8,471) $87,116 Share-based compensation 9,786 9,769 17,887 16,853 Other adjustments2 (12,424) - (6,340) - Tax adjustments3 485 (1,974) (2,123) (5,080) Adjusted net income $10,737 $57,080 $953 $98,889 Diluted earnings (loss) per share $0.24 $0.79 $(0.16) $1.42 Impact of adjustments (0.04) 0.13 0.18 0.19 Adjusted diluted earnings per share4 $0.20 $0.92 $0.02 $1.61 Reconciliation of net cash (used in) provided by operating activities to free cash flow
Six months ended
June 30 2026
2025
(Unaudited)Net cash (used in) provided by operating activities $(5,945) $101,384 Purchase of property and equipment (1,559) (1,951) Free cash flow $(7,504) $99,433 1 Represents costs of certain legal matters and employee actions outside the ordinary course of business.
2 Represents costs of certain legal matters and employee actions outside the ordinary course of business and, in the second quarter of 2026, a $13.539 million gain on repurchases of our exchangeable notes.
3 Represents the tax impact of (a) the reconciling items above and (b) other discrete tax items in 2025.
4 For the first half of 2026, the Weighted-average number of shares – diluted (thousands) used to calculate Adjusted diluted earnings per share is 55,927.
ODDITY TECH LTD.Supplemental Financial InformationU.S. dollar in thousandsCash, cash equivalents, and investments June 30,
December 31,
2026
2025
(Unaudited) (Audited) Cash, restricted cash, and cash equivalents $167,296 $402,279 Marketable securities 393,888 373,741 Total cash and investments $561,184 $776,020 Net revenue by sales channel
Three months ended Six months ended June 30,June 30, 2026
2025
2026
2025
(Unaudited) (Unaudited)Online direct-to-consumer $174,058 $235,161 $367,113 $496,214 Percent of net revenue 96% 98% 97% 97% Other (Israel retail, marketing affiliates) $6,459 $5,979 $11,344 $13,002 Percent of net revenue 4% 2% 3% 3% Net revenue $180,517 $241,140 $378,457 $509,216 Note: ODDITY does not sell to resellers or distributors. Online direct-to-consumer revenues are generated directly by ODDITY through its online platform only (i.e., ILMAKIAGE.com, SpoiledChild.com, and METHODIQ.com). All revenue in Israel, including revenue generated in stores, online, and from beauty academies, is included in Other.
Jamieson Wellness (OTCMKTS:JWLLF – Get Free Report) and ODDITY Tech (NASDAQ:ODD – Get Free Report) are both consumer staples companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.
Institutional and Insider Ownership 35.9% of ODDITY Tech shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Analyst Recommendations This is a summary of recent recommendations and price targets for Jamieson Wellness and ODDITY Tech, as provided by MarketBeat.
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jamieson Wellness 0 2 2 0 2.50 ODDITY Tech 4 9 0 0 1.69 ODDITY Tech has a consensus price target of $25.75, indicating a potential upside of 82.11%. Given ODDITY Tech’s higher possible upside, analysts plainly believe ODDITY Tech is more favorable than Jamieson Wellness. Profitability This table compares Jamieson Wellness and ODDITY Tech’s net margins, return on equity and return on assets.
Net Margins Return on Equity Return on Assets Jamieson Wellness N/A N/A N/A ODDITY Tech 6.97% 15.38% 4.99% Valuation and Earnings This table compares Jamieson Wellness and ODDITY Tech”s revenue, earnings per share and valuation.
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jamieson Wellness N/A N/A N/A N/A N/A ODDITY Tech $809.84 million 1.01 $110.75 million $0.79 17.90 ODDITY Tech has higher revenue and earnings than Jamieson Wellness.
Summary ODDITY Tech beats Jamieson Wellness on 6 of the 8 factors compared between the two stocks.
(Get Free Report)
Jamieson Wellness Inc., together with its subsidiaries, develops, manufactures, distributes, markets, and sells of branded and customer branded health products for humans in Canada, the United States, China and internationally. It operates through two segments, Jamieson Brands and Strategic Partners. The Jamieson Brands segment manufactures, distributes, and markets branded natural health products including vitamins, minerals, and supplements. The Strategic Partners segment provides contract manufacturing services to consumer health companies and retailers. The company offers health and wellness supplements under the Jamieson brand; health, beauty, and wellness supplements under the Youtheory brand; and foundational formulas, including probiotics, multivitamins, fish oils, vitamin D, and solution-focused products for better sleep or digestion under the Progressive brand. It also provides plant-based products under the Iron Vegan brand; natural health products for health concerns among women, including hormone imbalances, nutrient deficiencies, and sleep and stress management, and others under the Smart Solutions brand; and sports nutrition supplements under the Precision brand. The company offers its contract manufacturing services under the Nurticorp brand. It sells its products to distributors, and retail and wholesale customers. The company was formerly known as Jamieson Intermediate Holdings Ltd. and changed its name to Jamieson Wellness Inc. in May 2017. Jamieson Wellness Inc. was founded in 1922 and is headquartered in Toronto, Canada.
About ODDITY Tech (Get Free Report)
Oddity Tech Ltd. operates as a consumer tech company that builds digital-first brands for the beauty and wellness industries in the United States and internationally. It serves consumers worldwide through its AI-driven online platform, which uses data science, machine learning, and computer vision capabilities to identify consumer needs, and develop solutions in the form of beauty and wellness products. The company sells beauty, hair, and skin products under the IL MAKIAGE and SpoiledChild brands. In addition, it operates ODDITY LABS, a biotechnology center, which develops various ingredients, including novel molecules, probiotics, and peptides for beauty and wellness products. Oddity Tech Ltd. was incorporated in 2013 and is headquartered in Tel Aviv, Israel.
Receive News & Ratings for Jamieson Wellness Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jamieson Wellness and related companies with MarketBeat.com's FREE daily email newsletter.
On August 12, 2026, ODDITY Tech Ltd (ODD) shares rose 3.4% to a current price of $12.90. This price sits within a 52-week range of $9.25 to $64.23, highlighting
Empowered Funds LLC acquired a new position in ODDITY Tech Ltd. (NASDAQ:ODD – Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 95,323 shares of the company’s stock, valued at approximately $1,275,000. Empowered Funds LLC owned approximately 0.17% of ODDITY Tech at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Wexford Capital LP purchased a new stake in shares of ODDITY Tech during the third quarter worth about $40,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in ODDITY Tech by 134.8% in the 3rd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 1,134 shares of the company’s stock worth $69,000 after purchasing an additional 651 shares in the last quarter. USS Investment Management Ltd grew its position in ODDITY Tech by 5.3% during the 4th quarter. USS Investment Management Ltd now owns 13,753 shares of the company’s stock worth $552,000 after purchasing an additional 695 shares during the last quarter. California State Teachers Retirement System increased its stake in ODDITY Tech by 2.0% during the 4th quarter. California State Teachers Retirement System now owns 43,532 shares of the company’s stock valued at $1,749,000 after purchasing an additional 870 shares in the last quarter. Finally, Entropy Technologies LP raised its holdings in shares of ODDITY Tech by 10.0% in the third quarter. Entropy Technologies LP now owns 9,900 shares of the company’s stock worth $617,000 after buying an additional 900 shares during the last quarter. 35.88% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes Several equities research analysts have recently commented on the stock. Needham & Company LLC reiterated a “hold” rating on shares of ODDITY Tech in a research note on Tuesday, June 2nd. Jefferies Financial Group reaffirmed a “hold” rating and set a $10.25 price target on shares of ODDITY Tech in a research report on Tuesday, June 2nd. Morgan Stanley dropped their price target on ODDITY Tech from $16.00 to $10.00 and set an “equal weight” rating on the stock in a research note on Wednesday, June 3rd. Barclays cut their price objective on ODDITY Tech from $13.00 to $8.00 and set an “underweight” rating on the stock in a report on Wednesday, June 3rd. Finally, Wall Street Zen downgraded ODDITY Tech from a “sell” rating to a “strong sell” rating in a report on Saturday, April 18th. Nine research analysts have rated the stock with a Hold rating and four have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Reduce” and an average price target of $25.39.
Check Out Our Latest Stock Report on ODD
ODDITY Tech Stock Performance NASDAQ ODD opened at $14.12 on Friday. The firm has a market capitalization of $812.96 million, a P/E ratio of 17.87 and a beta of 2.38. The stock has a 50-day simple moving average of $14.32 and a two-hundred day simple moving average of $17.35. The company has a debt-to-equity ratio of 1.96, a quick ratio of 2.86 and a current ratio of 4.06. ODDITY Tech Ltd. has a fifty-two week low of $9.25 and a fifty-two week high of $64.23.
ODDITY Tech (NASDAQ:ODD – Get Free Report) last issued its earnings results on Tuesday, June 2nd. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.13). The company had revenue of $197.94 million during the quarter, compared to analysts’ expectations of $187.87 million. ODDITY Tech had a return on equity of 15.38% and a net margin of 6.97%.The firm’s quarterly revenue was down 26.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.69 EPS. On average, equities analysts forecast that ODDITY Tech Ltd. will post -0.55 earnings per share for the current year.
Insider Buying and Selling In other news, CFO Mann Lindsay Drucker sold 11,473 shares of the firm’s stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $15.10, for a total transaction of $173,242.30. Following the sale, the chief financial officer owned 104,492 shares of the company’s stock, valued at $1,577,829.20. This trade represents a 9.89% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 130,678 shares of company stock valued at $1,956,201.
ODDITY Tech Profile (Free Report)
Oddity Tech Ltd. operates as a consumer tech company that builds digital-first brands for the beauty and wellness industries in the United States and internationally. It serves consumers worldwide through its AI-driven online platform, which uses data science, machine learning, and computer vision capabilities to identify consumer needs, and develop solutions in the form of beauty and wellness products. The company sells beauty, hair, and skin products under the IL MAKIAGE and SpoiledChild brands.
Read More Five stocks we like better than ODDITY Tech Quantum Earnings Week: Winners and Losers Are Finally Emerging Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish Want to see what other hedge funds are holding ODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ODDITY Tech Ltd. (NASDAQ:ODD – Free Report).
Receive News & Ratings for ODDITY Tech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ODDITY Tech and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINE9,674 Shares in Granite Construction Incorporated $GVA Acquired by Empowered Funds LLC
NEXT HEADLINE »California State Teachers Retirement System Buys 12,878 Shares of Whirlpool Corporation $WHR
Amundi raised its stake in shares of ODDITY Tech Ltd. (NASDAQ:ODD – Free Report) by 17.8% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 434,945 shares of the company’s stock after purchasing an additional 65,647 shares during the quarter. Amundi owned 0.76% of ODDITY Tech worth $5,820,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors have also recently made changes to their positions in ODD. Wexford Capital LP purchased a new position in ODDITY Tech in the third quarter worth $40,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of ODDITY Tech by 134.8% during the 3rd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 1,134 shares of the company’s stock valued at $69,000 after purchasing an additional 651 shares during the last quarter. Legal & General Group Plc purchased a new position in shares of ODDITY Tech during the 2nd quarter valued at about $71,000. SG Americas Securities LLC bought a new stake in ODDITY Tech in the 1st quarter worth approximately $104,000. Finally, Headlands Technologies LLC bought a new stake in ODDITY Tech in the 2nd quarter worth approximately $108,000. Institutional investors own 35.88% of the company’s stock.
ODDITY Tech Stock Down 0.6% Shares of ODDITY Tech stock opened at $15.22 on Thursday. The company has a debt-to-equity ratio of 1.96, a quick ratio of 2.86 and a current ratio of 4.06. ODDITY Tech Ltd. has a 52-week low of $9.25 and a 52-week high of $64.23. The company’s 50 day moving average price is $14.30 and its 200-day moving average price is $17.53. The stock has a market capitalization of $876.29 million, a price-to-earnings ratio of 19.27 and a beta of 2.38.
ODDITY Tech (NASDAQ:ODD – Get Free Report) last announced its quarterly earnings results on Tuesday, June 2nd. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.13). The firm had revenue of $197.94 million during the quarter, compared to the consensus estimate of $187.87 million. ODDITY Tech had a return on equity of 15.38% and a net margin of 6.97%.ODDITY Tech’s revenue was down 26.2% on a year-over-year basis. During the same period last year, the business earned $0.69 EPS. Equities research analysts forecast that ODDITY Tech Ltd. will post -0.55 EPS for the current year.
Insider Buying and Selling In related news, CFO Mann Lindsay Drucker sold 11,473 shares of the firm’s stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $15.10, for a total value of $173,242.30. Following the completion of the sale, the chief financial officer owned 104,492 shares of the company’s stock, valued at $1,577,829.20. This trade represents a 9.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 130,678 shares of company stock valued at $1,956,201 over the last ninety days.
Wall Street Analysts Forecast Growth A number of equities research analysts have recently issued reports on the stock. Morgan Stanley cut their price objective on shares of ODDITY Tech from $16.00 to $10.00 and set an “equal weight” rating for the company in a research note on Wednesday, June 3rd. Jefferies Financial Group reissued a “hold” rating and issued a $10.25 price target on shares of ODDITY Tech in a research note on Tuesday, June 2nd. Wall Street Zen lowered shares of ODDITY Tech from a “sell” rating to a “strong sell” rating in a research report on Saturday, April 18th. Needham & Company LLC reaffirmed a “hold” rating on shares of ODDITY Tech in a research note on Tuesday, June 2nd. Finally, KeyCorp reiterated a “sector weight” rating on shares of ODDITY Tech in a report on Wednesday, June 3rd. Eight investment analysts have rated the stock with a Hold rating and five have given a Sell rating to the stock. According to data from MarketBeat, ODDITY Tech presently has a consensus rating of “Reduce” and an average price target of $25.39.
Get Our Latest Report on ODD
About ODDITY Tech (Free Report)
Oddity Tech Ltd. operates as a consumer tech company that builds digital-first brands for the beauty and wellness industries in the United States and internationally. It serves consumers worldwide through its AI-driven online platform, which uses data science, machine learning, and computer vision capabilities to identify consumer needs, and develop solutions in the form of beauty and wellness products. The company sells beauty, hair, and skin products under the IL MAKIAGE and SpoiledChild brands.
Featured Stories Five stocks we like better than ODDITY Tech SpaceX: Love the Company, But the Stock Is a Harder Call Ulta’s Growth Is Real, But So Are the Risks BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth
Receive News & Ratings for ODDITY Tech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ODDITY Tech and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINELazard, Inc. $LAZ Shares Bought by Amundi
NEXT HEADLINE »Amundi Has $5.10 Million Position in Popular, Inc. $BPOP
NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- ODDITY Tech Ltd. (NASDAQ: ODD) today announced that it will release its second quarter 2026 financial results before the market open on Wednesday, September 9, 2026, to be followed by a conference call at 8:30 a.m. Eastern Time.
Conference Call Details:
To participate in the conference call, please dial 1-877-407-9208 (US) or 1-201-493-6784 (international). To access the call, please reference the company name and call title: ODDITY Second Quarter 2026 Earnings Call. A webcast of the call will be accessible on the Investors section of ODDITY’s website at https://investors.oddity.com. A recording will be available shortly after the conclusion of the call. To access the replay, please dial 1-844-512-2921 (US) or 1-412-317-6671 (international). The access code for the replay is 13761986. An archive of the webcast will be available on the Investors section of ODDITY’s website for seven days following the call.
About ODDITY
ODDITY is a consumer tech company that builds and scales digital-first brands to disrupt the offline-dominated beauty and wellness industries. The company serves approximately 68 million users with its AI-driven online platform, deploying data science to identify consumer needs, and developing solutions in the form of beauty and wellness products. ODDITY owns IL MAKIAGE, SpoiledChild and METHODIQ. The company operates with business headquarters in New York City, an R&D center in Tel Aviv, Israel, and a biotechnology lab in Boston.
REX Shares ("REX") and Tuttle Capital Management ("TCM") today announce that listed options are now available on the T-REX 2X Long SpaceX Daily Target ETF (NYSE Arca: SPAX), giving traders an additional way to express tactical views on one of the most closely watched names in the public market.
SPAX is designed to deliver 200% of the daily stock price performance of Space Exploration Technologies Corporation (Nasdaq: SPCX), before fees and expenses. With options now listed, traders can use calls, puts, and multi-leg strategies alongside the fund itself to manage exposure, define risk parameters, or position around the elevated volatility that has characterized SPCX since its public debut. Options on SPAX add a layer of flexibility on top of a product that already delivers leveraged daily exposure inside a liquid, transparent ETF.
"Few names generate the kind of conviction SpaceX does, and SPAX has given traders a way to act on it," said Greg King, CEO and Founder of REX. "With listed options, they can now define risk, target a daily view, and build multi-leg strategies around that conviction.”
"Layering a listed options market on top of a 2X single-stock ETF is about as much firepower as you can hand an active trader," added Matt Tuttle, CEO and CIO of Tuttle Capital Management. "SpaceX moves, and that kind of volatility is exactly what makes options on a leveraged SpaceX product so useful."
SPAX is among a growing number of T-REX funds to gain a listed options market, reflecting rising trader demand for more precise ways to play single-stock volatility. The suite now includes over 40 leveraged and inverse single-stock ETFs, among them first-to-market 2X exposures to Robinhood (ROBN), Nvidia (NVDX), and Tesla (TSLT).
Investing in the Fund is not equivalent to investing directly in SPCX.
Options involve risk and are not suitable for all investors. Prior to buying or selling an option, investors must read a copy of the Characteristics and Risks of Standardized Options, also known as the options disclosure document (ODD). It explains the characteristics and risks of exchange traded options and is available from your broker or from The Options Clearing Corporation. Options carry the risk of losing the entire premium paid in a relatively short period, and certain strategies can expose an investor to losses that exceed the initial investment.
Investing in the fund involves significant risk and is for sophisticated investors. The Fund is not suitable for all investors. The Fund is designed to be utilized only by knowledgeable investors who understand the potential consequences of seeking daily leveraged (2X) investment results, understand the risks associated with the use of leverage and are willing to monitor their portfolios frequently. The Fund is not intended to be used by, and is not appropriate for, investors who do not intend to actively monitor and manage their portfolios. For periods longer than a single day, the Fund will lose money if SPCX's performance is flat, and it is possible that the Fund will lose money even if SPCX's performance increases over a period longer than a single day. An investor could lose the full principal value of his/her investment within a single day if the price of SPCX falls by more than 50% in one trading day.
For full fund information, holdings, and risk disclosures, visit rexshares.com.
About T-REX
The T-REX lineup is a partnership between REX Shares and Tuttle Capital Management. T-REX is redefining single-stock ETFs with first-to-market leveraged and inverse exposures. Built to deliver 2x and -2x daily performance on some of the market's most dynamic companies, T-REX funds give traders powerful tools to express high-conviction views. From being the first to launch 2x and -2x ETFs on Tesla (TSLT) and Nvidia (NVDX), to pioneering the first leveraged 2x ETFs tied to spot Bitcoin (BTCL), T-REX continues to set the pace in ETF innovation. With more than 40 products already trading, the suite is constantly expanding to meet evolving investor demand for tactical, high-impact exposures. For more information, visit rexshares.com.
About REX Shares
REX Shares offers a suite of exchange-traded products built for both active traders and long-term investors, spanning income, leveraged, thematic, and crypto strategies. Whether making short-term trades, generating income from volatility, or investing in digital assets and emerging themes like drones, REX empowers investors to act on strong market views. For more information, please visit rexshares.com.
About Tuttle Capital Management
Tuttle Capital Management is a leader in thematic and actively managed ETFs, leveraging an agile investment approach to align with market trends. Please visit www.tuttlecap.com for more information.
This ETF does not invest directly in the referenced asset and has a higher degree of risk since it is seeking to track a single stock or asset.
A link to the Fund's prospectus can be found here. Click here for fund holdings.
Investors should consider the investment objectives, risk, charges, and expenses carefully before investing. For a prospectus or summary prospectus with this and other information about the T-REX ETFs please call 1-844-802-4004 or visit our website at rexshares.com. Read the prospectus and summary prospectus carefully before investing.
There is no guarantee that the Fund will achieve its investment objective. Investing involves risk, including possible loss of principal.
Important Risks
Investing in a REX Shares ETF may be more volatile than investing in broadly diversified funds. The use of leverage by a Fund increases the risk to the Fund. The REX Shares ETFs are not suitable for all investors and should be utilized only by sophisticated investors who understand leverage risk, consequences of seeking daily leveraged, or daily inverse leveraged, investment results and intend to actively monitor and manage their investment.
An investment in the Fund entails risk. The Fund may not achieve its leveraged investment objective and there is a risk that you could lose all of your money invested in the Fund. The Fund is not a complete investment program. In addition, the Fund presents risks not traditionally associated with other mutual funds and ETFs. It is important that investors closely review all of the risks listed below and understand them before making an investment in the Fund.
Options Risk. The Fund and its shares may be the reference asset for listed options. Options are complex instruments and may be more volatile than the underlying shares. The use of options may involve risks different from, or greater than, the risks associated with investing directly in the Fund, including the risk that an option may expire worthless and the risk of significant or total loss of the premium paid.
Effects of Compounding and Market Volatility Risk. The Fund has a daily leveraged investment objective and the Fund's performance for periods greater than a trading day will be the result of each day's returns compounded over the period, which is very likely to differ from 200% of the underlying's performance, before fees and expenses. Compounding affects all investments, but has a more significant impact on funds that are leveraged and that rebalance daily and becomes more pronounced as volatility and holding periods increase.
Leverage Risk. The Fund obtains investment exposure in excess of its net assets by utilizing leverage and may lose more money in market conditions that are adverse to its investment objective than a fund that does not utilize leverage. An investment in the Fund is exposed to the risk that a decline in the daily performance of the underlying stock will be magnified. This means that an investment in the Fund will be reduced by an amount equal to 2% for every 1% daily decline in the underlying, not including the costs of financing leverage and other operating expenses, which would further reduce its value.
SpaceX Investing Risk. SpaceX is a commercial space transportation and aerospace technology company whose business model is dependent on the successful development, launch and operation of complex space systems, including launch vehicles, spacecraft and satellite constellations.
Liquidity Risk. Holdings of the Fund may be difficult to buy or sell or may be illiquid, particularly during times of market turmoil. Illiquid securities may be difficult to value, especially in changing or volatile markets.
Non-Diversification Risk. The Fund is classified as "non-diversified" under the Investment Company Act of 1940, as amended. This means it has the ability to invest a relatively high percentage of its assets in the securities of a small number of issuers or in financial instruments with a single counterparty or a few counterparties.
Distributor: Foreside Fund Services, LLC, member FINRA, not affiliated with REX Shares or the Funds' investment advisor.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260616940253/en/
Oddity Tech is downgraded from buy to hold due to unresolved customer acquisition cost headwinds and weak first-order growth. Q1 2026 revenue declined 26% y/y, with first orders down ~50% and margins deteriorating; Q2 guidance suggests continued revenue contraction. The investment thesis now hinges on whether CPA normalization is temporary or structural, as elevated CPA undermines the core acquisition engine.
New York, New York--(Newsfile Corp. - May 9, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ODDITY Tech Ltd. (NASDAQ: ODD) between February 26, 2025 and February 24, 2026, inclusive (the "Class Period"), of the important May 11, 2026 lead plaintiff deadline.
SO WHAT: If you purchased Oddity securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Oddity class action, go to https://rosenlegal.com/submit-form/?case_id=27381 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 11, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) due to an algorithm change by Oddity's largest advertising partner, Oddity's advertisements were being diverted to lower quality auctions at abnormally high costs; (2) the foregoing significantly increased Oddity's customer acquisition costs, thereby negatively impacting Oddity's business and financial prospects; (3) accordingly, defendants overstated the overall strength, stability, and sustainability of Oddity's digital operating model and/or market position; and (4) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Oddity class action, go to https://rosenlegal.com/submit-form/?case_id=27381 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/296710
Source: The Rosen Law Firm PA
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
San Francisco, California--(Newsfile Corp. - May 9, 2026) - Hagens Berman, a global shareholder rights law firm, updates investors in ODDITY Tech Ltd. (NASDAQ: ODD) regarding the pending securities class action lawsuit following a massive 49% stock collapse. The firm reminds investors that the deadline to move for Lead Plaintiff is May 11, 2026.
SUBMIT YOUR LOSSES TO HAGENS BERMAN NOW
The ODD Securities Class Action: When Did ODDITY Know About the Dislocation?
The lawsuit against ODDITY, a consumer tech company that uses AI to sell beauty products, alleges the company misrepresented the stability of its digital operating model. While ODDITY repeatedly assured investors that its AI platform would sustain high growth and attractive margins, it allegedly failed to disclose a critical disruption.
On February 25, 2026, ODDITY admitted it had experienced a dislocation in its primary advertising account due to algorithm changes by its largest partner. This change diverted ODDITY's ads to lower-quality auctions at abnormally high costs, causing:
Spiking Customer Acquisition Costs (CAC): Advertising efficiency plummeted, directly impacting margins.Severe Revenue Contraction: The company projected a staggering 30% year-over-year revenue decline for Q1 2026.Delayed Disclosure: During an earnings call, management admitted they "observed that something was different in the second half of 2025," yet they continued to issue optimistic growth guidance as late as November 2025.Wall Street Reaction and Market Impact
The disclosure triggered a massive selloff. ODDITY's shares fell $14.28 per share, or nearly 50%, to close at $14.74 on February 25, 2026, wiping out more than $600 million in market capitalization. In the wake of this news, major Wall Street firms, including JPMorgan and Bank of America, cut their ratings on the stock.
"We are investigating whether ODDITY knowingly issued false statements during the second half of 2025 while privately watching its primary growth engine fail," said Reed Kathrein, the Hagens Berman partner leading the investigation.
Lead Plaintiff Deadline: May 11, 2026
Investors who purchased ODDITY securities between February 26, 2025, and February 24, 2026, and suffered losses, have until May 11, 2026, to seek a lead role in the litigation.
Report Your ODD Investment Losses Now Visit: www.hbsslaw.com/cases/oddity Email: [email protected] Call 844-916-0895Whistleblowers: Persons with non-public information regarding ODDITY should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].
# # #
About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
Contact:
Reed Kathrein, 844-916-0895
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/296656
Source: Hagens Berman Sobol Shapiro LLP
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Oddity To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Oddity between February 26, 2025 and February 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
New York, New York--(Newsfile Corp. - May 9, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Oddity Tech Ltd. ("Oddity" or the "Company") (NASDAQ: ODD) and reminds investors of the May 11, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) due to an algorithm change by Oddity's largest advertising partner, Oddity's advertisements were being diverted to lower quality auctions at abnormally high costs; (ii) the foregoing significantly increased Oddity's customer acquisition costs, thereby negatively impacting Oddity's business and financial prospects; (iii) accordingly, Defendants overstated the overall strength, stability, and sustainability of Oddity's digital operating model and/or market position; and (iv) as a result, Defendants' public statements were materially false and misleading at all relevant times.
On February 25, 2026, Oddity reported its full year 2025 financial results, disclosing that Oddity "experienced a dislocation in our account with our largest advertising partner that we believe was driven by algorithm changes which diverted us to lower quality auctions at abnormally high costs. This is resulting in significant increases in new user acquisition costs that are not correlated with the market or our historical experience."
On this news, the price of Oddity stock fell more than 49%.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Oddity's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Oddity Tech class action, go to www.faruqilaw.com/ODD or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/296493
Source: Faruqi & Faruqi LLP
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
New York, New York--(Newsfile Corp. - May 10, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ODDITY Tech Ltd. (NASDAQ: ODD) between February 26, 2025 and February 24, 2026, inclusive (the "Class Period"), of the important May 11, 2026 lead plaintiff deadline.
SO WHAT: If you purchased Oddity securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Oddity class action, go to https://rosenlegal.com/submit-form/?case_id=27381 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 11, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) due to an algorithm change by Oddity's largest advertising partner, Oddity's advertisements were being diverted to lower quality auctions at abnormally high costs; (2) the foregoing significantly increased Oddity's customer acquisition costs, thereby negatively impacting Oddity's business and financial prospects; (3) accordingly, defendants overstated the overall strength, stability, and sustainability of Oddity's digital operating model and/or market position; and (4) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Oddity class action, go to https://rosenlegal.com/submit-form/?case_id=27381 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/296711
Source: The Rosen Law Firm PA
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
SAN FRANCISCO, May 10, 2026 (GLOBE NEWSWIRE) -- Hagens Berman, a global shareholder rights law firm, updates investors in ODDITY Tech Ltd. (NASDAQ: ODD) regarding the pending securities class action lawsuit following a massive 49% stock collapse. The firm reminds investors that the deadline to move for Lead Plaintiff is May 11, 2026.
SUBMIT YOUR LOSSES TO HAGENS BERMAN NOW
The ODD Securities Class Action: When Did ODDITY Know About the Dislocation?
The lawsuit against ODDITY, a consumer tech company that uses AI to sell beauty products, alleges the company misrepresented the stability of its digital operating model. While ODDITY repeatedly assured investors that its AI platform would sustain high growth and attractive margins, it allegedly failed to disclose a critical disruption.
On February 25, 2026, ODDITY admitted it had experienced a dislocation in its primary advertising account due to algorithm changes by its largest partner. This change diverted ODDITY’s ads to lower-quality auctions at abnormally high costs, causing:
Spiking Customer Acquisition Costs (CAC): Advertising efficiency plummeted, directly impacting margins.Severe Revenue Contraction: The company projected a staggering 30% year-over-year revenue decline for Q1 2026.Delayed Disclosure: During an earnings call, management admitted they "observed that something was different in the second half of 2025," yet they continued to issue optimistic growth guidance as late as November 2025.
Wall Street Reaction and Market Impact
The disclosure triggered a massive selloff. ODDITY’s shares fell $14.28 per share, or nearly 50%, to close at $14.74 on February 25, 2026, wiping out more than $600 million in market capitalization. In the wake of this news, major Wall Street firms, including JPMorgan and Bank of America, cut their ratings on the stock.
“We are investigating whether ODDITY knowingly issued false statements during the second half of 2025 while privately watching its primary growth engine fail,” said Reed Kathrein, the Hagens Berman partner leading the investigation.
Lead Plaintiff Deadline: May 11, 2026
Investors who purchased ODDITY securities between February 26, 2025, and February 24, 2026, and suffered losses, have until May 11, 2026, to seek a lead role in the litigation.
Report Your ODD Investment Losses NowVisit: www.hbsslaw.com/cases/oddityEmail: [email protected] 844-916-0895 Whistleblowers: Persons with non-public information regarding ODDITY should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].
About Hagens Berman
Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ODDITY Tech Ltd. (NASDAQ: ODD) between February 26, 2025 and February 24, 2026, inclusive (the “Class Period”), of the important May 11, 2026 lead plaintiff deadline.
SO WHAT: If you purchased Oddity securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Oddity class action, go to https://rosenlegal.com/submit-form/?case_id=27381 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 11, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) due to an algorithm change by Oddity’s largest advertising partner, Oddity’s advertisements were being diverted to lower quality auctions at abnormally high costs; (2) the foregoing significantly increased Oddity’s customer acquisition costs, thereby negatively impacting Oddity’s business and financial prospects; (3) accordingly, defendants overstated the overall strength, stability, and sustainability of Oddity’s digital operating model and/or market position; and (4) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Oddity class action, go to https://rosenlegal.com/submit-form/?case_id=27381 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827 [email protected]
www.rosenlegal.com
New York, New York--(Newsfile Corp. - May 10, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against ODDITY Tech Ltd. (NASDAQ: ODD) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Oddity securities between February 26, 2025 and February 24, 2026, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/ODD.
Oddity Case Details
The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose material adverse facts concerning the Company's business, operations, and prospects. Specifically, the Complaint alleges that Defendants failed to disclose that:
following an algorithm change by the Company's largest advertising partner, the Company's advertisements were diverted to lower-quality auctions at abnormally high costs; as a result, the Company's customer acquisition costs increased significantly, negatively impacting its business and financial prospects; Defendants therefore overstated the strength, stability, and sustainability of the Company's digital operating model and market position; and as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.What's Next for Oddity Investors?
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/ODD, or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Oddity you have until May 11, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
No Cost to Oddity Investors
We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for Oddity Securities Class Action?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising.
Prior results do not guarantee similar outcomes.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/295575
Source: Bronstein, Gewirtz & Grossman, LLC
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
LOS ANGELES, May 11, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Oddity Tech Ltd. (“Oddity” or “the Company”) (NASDAQ: ODD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company’s securities between February 26, 2025 and February 24, 2026, inclusive (the “Class Period”), are encouraged to contact the firm before May 11, 2026.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Oddity’s advertisements were diverted to poor quality auctions at high costs due to an algorithm change by one of its largest ad partners. The Company’s customer acquisition costs increased significantly due to this change, harming its business. The Company overstates the strength of its operating model. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Oddity, investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335 [email protected]
NEW YORK--(BUSINESS WIRE)---- $ODD #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Oddity Tech Ltd. (“Oddity” or the “Company”) (NASDAQ: ODD) and reminds investors of the May 11, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has reco.
New York, New York--(Newsfile Corp. - May 11, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against ODDITY Tech Ltd. (NASDAQ: ODD) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Oddity securities between February 26, 2025 and February 24, 2026, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/ODD.
Oddity Case Details
The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose material adverse facts concerning the Company's business, operations, and prospects. Specifically, the Complaint alleges that Defendants failed to disclose that:
following an algorithm change by the Company's largest advertising partner, the Company's advertisements were diverted to lower-quality auctions at abnormally high costs; as a result, the Company's customer acquisition costs increased significantly, negatively impacting its business and financial prospects; Defendants therefore overstated the strength, stability, and sustainability of the Company's digital operating model and market position; and as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.What's Next for Oddity Investors?
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/ODD, or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Oddity you have until May 11, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
No Cost to Oddity Investors
We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for Oddity Securities Class Action?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising.
Prior results do not guarantee similar outcomes.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/295576
Source: Bronstein, Gewirtz & Grossman, LLC
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
New York, New York--(Newsfile Corp. - May 11, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ODDITY Tech Ltd. (NASDAQ: ODD) between February 26, 2025 and February 24, 2026, inclusive (the "Class Period"), of the important May 11, 2026 lead plaintiff deadline.
SO WHAT: If you purchased Oddity securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Oddity class action, go to https://rosenlegal.com/submit-form/?case_id=27381 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 11, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) due to an algorithm change by Oddity's largest advertising partner, Oddity's advertisements were being diverted to lower quality auctions at abnormally high costs; (2) the foregoing significantly increased Oddity's customer acquisition costs, thereby negatively impacting Oddity's business and financial prospects; (3) accordingly, defendants overstated the overall strength, stability, and sustainability of Oddity's digital operating model and/or market position; and (4) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Oddity class action, go to https://rosenlegal.com/submit-form/?case_id=27381 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/296922
Source: The Rosen Law Firm PA
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
SAN FRANCISCO, May 11, 2026 /PRNewswire/ -- Hagens Berman, a global shareholder rights law firm, updates investors in ODDITY Tech Ltd. (NASDAQ: ODD) regarding the pending securities class action lawsuit following a massive 49% stock collapse.
, /PRNewswire/ -- A securities class action lawsuit has been filed against ODDITY Tech. Ltd. (NASDAQ: ODD), seeking to represent investors who purchased ODDITY securities between February 26, 2025 and February 24, 2026.
The lawsuit follows the 49% decline in the price of ODDITY American Depositary Shares on February 25, 2026. The selloff, which wiped out over $600 million dollars of the company's market capitalization, was triggered by the company's announcement that it expects a whopping 30% year-over-year decline in its Q1 2026 revenue.
The development and severe market reaction have prompted national shareholders rights firm Hagens Berman to investigate claims that ODDITY violated the federal securities laws.
The firm urges investors in ODDITY who suffered significant losses to submit your losses now. The firm also encourages witnesses who may be able to assist in the investigation to contact its attorneys.
Class Period: Feb. 26, 2025 – Feb. 24, 2026
Lead Plaintiff Deadline: May 11, 2026
Visit: www.hbsslaw.com/investor-fraud/odd
Contact the Firm Now: [email protected]
844-916-0895
ODDITY Tech. Ltd. (ODD) Securities Class Action:
The lawsuit is focused on ODDITY's repeated touting of its AI-driven online platform, which the company assured investors would "sustain our high-growth and attractive margin profile[.]"
The complaint alleges that ODDITY made false and misleading statements while failing to disclose crucial information to investors, including an algorithm change by the company's largest advertising partner which resulted in the diversion of ODDITY's advertisements to lower quality auctions at abnormally high costs.
This, in turn, significantly increased ODDITY's customer acquisition costs and negatively affected the company's business and financial prospects.
In addition, the complaint alleges, the foregoing resulted in the company's overstating the overall strength, stability, and sustainability of ODDITY's digital operating model.
Investors' expectations were dashed on February 25, 2026, when ODDITY announced its Q4 and FY 2025 financial results and revealed that "we experienced a dislocation in our account with our largest advertising partner that we believe was driven by algorithm changes which diverted us to lower quality auctions at abnormally high costs" that drove new user acquisition costs significantly higher.
During the related earnings call, an analyst pressed management about when ODDITY first knew of the dislocation, but management would only say that they had "observed that something was different in the second half of 2025" – that is, without acknowledging when the issue actually started.
As concerning, ODDITY quantified the effects of the dislocation, saying that Q1 2026 revenue would decline 30% year-over-year.
"We're investigating when ODDITY first knew of the dislocation issue and whether it may have intentionally misled investors about the true strength of its AI growth-driver," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation.
If you invested in ODDITY and have substantial losses, or have knowledge that may assist the firm's investigation, submit your losses now »
If you'd like more information and answers to additional frequently asked questions about the ODDITY case and the firm's investigation, read more »
Whistleblowers: Persons with non-public information regarding ODDITY should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].
About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- ODDITY Tech Ltd. (“ODDITY”) (NASDAQ: ODD), today announced that it will release its first quarter 2026 financial results before the market open on Tuesday, June 2, 2026, to be followed by a conference call at 8:30 a.m. Eastern Time.
Conference Call Details:
To participate in the conference call, please dial 1-877-407-9208 (US) or 1-201-493-6784 (international). To access the call, please reference the company name and call title: ODDITY First Quarter 2026 Earnings Call. A webcast of the call will be accessible on the Investors section of ODDITY’s website at https://investors.oddity.com. A recording will be available shortly after the conclusion of the call. To access the replay, please dial 1-844-512-2921 (US) or 1-412-317-6671 (international). The access code for the replay is 13760709. An archive of the webcast will be available on the Investors section of ODDITY’s website for seven days following the call.
About ODDITY
ODDITY is a consumer tech company that builds and scales digital-first brands to disrupt the offline-dominated beauty and wellness industries. The company serves approximately 68 million users with its AI-driven online platform, deploying data science to identify consumer needs, and developing solutions in the form of beauty and wellness products. ODDITY owns IL MAKIAGE, SpoiledChild and METHODIQ. The company operates with business headquarters in New York City, an R&D center in Tel Aviv, Israel, and a biotechnology lab in Boston.
Oddity's 2025 base still looks strong, but Q1 will test my ad reset contrarian thesis. The real issue is whether Try Before You Buy can still scale through paid social. Fortunately, they have a relatively liquid balance sheet, and the increased buyback could help support their stock price going forward.
First quarter net revenue of $197.9 million, down approximately 26% year-over-yearFirst quarter adjusted EBITDA of $(7.0) millionFirst quarter net loss of $(21.4) million and first quarter adjusted net loss of $(9.8) millionStrong liquidity position including cash, cash equivalents and investments of $667.4 million, and aggregate credit facilities of $350 million which remain undrawn NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- ODDITY Tech Ltd. (NASDAQ: ODD) today announced its financial results for the first quarter ended March 31, 2026.
“We continue to implement our recovery plan to address the account dislocation with our largest advertising partner and we remain hopeful that we are on track for normalization in the second half of this year,” said Oran Holtzman, ODDITY co-founder and CEO. “For many years, our CPA was very stable, with only gradual increases aligned with our industry. In Q1 2026, we saw a severe step-function discontinuity, comparing to historical first quarters, with CPA in some cases reaching levels 2x higher than what we expected. While we continue to navigate this dislocation, we have been working closely with our advertising partner on remediation and we are encouraged by an improvement in IL MAKIAGE CPA this May, which declined an estimated -28% sequentially from April.”
Media Costs
ODDITY is providing additional data on IL MAKIAGE CPA with our largest advertising partner for H1 2022 through May of H1 2026, as the first half is historically the period in which we acquire the majority of our annual new users. We believe this data supports the view that the CPA dislocation is technical in nature, rather than driven by brand health or market saturation.
Prior to 2026, IL MAKIAGE 1H CPA growth was very stable, with yearly increases correlated with our industry.The increase in 2026 is sudden, indicating a dramatic break rather than steady deterioration over time.The breakdown occurred in different markets simultaneously. US, Canada, UK, Australia, Israel — markets with different longevity and saturation levels.A driver of the break is spiking bounce rates. This shows in our view that the issue is with lower quality audiences being served our ads by the algorithm. IL MAKIAGE CPA Index with Largest Advertising Partner, Internal Attribution System
Half-Year
CPA INDEX
YOY % CHG
H122
1.0
H123
1.2
16
%
H124
1.3
14
%
H125
1.5
15
%
H1 through May 26
2.8
83
%
First Quarter 2026 Summary
ODDITY achieved key objectives during the first quarter, including:
Exceeded our first quarter revenue outlook issued February 25, 2026 of an approximately 30% decline.Positive inflection in IL MAKIAGE CPA’s trend in May, reflecting progress resetting our ad account signals.Remediation work in IL MAKIAGE Try Before You Buy, and a shift of 40% of acquisition revenue out of Try Before You Buy and into Buy.A strong start for our newest brand, METHODIQ, which remains on track to deliver year 1 results in-line with those of SpoiledChild.Ongoing development and expansion of the ODDITY Labs molecule discovery platform.Strong liquidity position including cash, cash equivalents and investments of $667.4 million, and aggregate credit facilities of $350 million which remain undrawn. “We are pleased with the progress we see in our remediation work and with our ability to deliver first quarter revenue above our guidance,” said Lindsay Drucker Mann, ODDITY Global CFO. “The CPA dislocation led to a sharp decline in first orders during the quarter, and the loss of these first orders will negatively impact our repeat business across the year. We therefore expect Q2 net revenue will decline between 25 and 30% year-over-year, and hope to see sequential improvement in the second half of 2026.”
Profitability Drivers
Adjusted EBITDA was materially negatively impacted by higher CPA and ODDITY’s decision to spend on acquisition during the quarter, in an effort to remedy the account dislocation. This led to significantly lower revenue generated on like for like media spend. Reduced media efficiency coupled with continued investment in growth initiatives drove meaningful operating expense deleverage.
Gross margin compression in the period was driven in part by product and brand mix and a low single digit decline in average order value (AOV). ODDITY’s remediation activity during the quarter, which included running various tests to try and isolate the dislocation in its advertising account, negatively impacted Q1 margins.
Share Buyback Program
In March 2026, ODDITY’s Board of Directors approved a share buyback program authorizing the repurchase of up to $200 million of the Company’s Class A ordinary shares. The new authorization expires on March 31, 2029 or upon full deployment of the allocated funds, subject to any future modifications by the Board.
ODDITY repurchased approximately 6.1 million Class A ordinary shares during the first quarter for approximately $82.3 million, reducing Class A ordinary shares outstanding by approximately 10.6%. ODDITY exited the first quarter with approximately $167.3 million remaining under the authorization, subject to market conditions, legal and regulatory constraints.
First Quarter Fiscal 2026 Financial Highlights:
Results for the first quarter ended March 31, 2026 are presented below in comparison to the first quarter ended March 31, 2025.
Net revenue was $197.9 million compared to $268.1 million in the first quarter of 2025, a decrease of 26%.Gross profit was $138.0 million compared to $200.8 million in the first quarter of 2025; gross margin was 69.7% compared to 74.9% in the first quarter of 2025.Net loss was $(21.4) million compared to net income of $37.8 million in the first quarter of 2025.Adjusted net loss was $(9.8) million compared to adjusted net income of $41.8 million in the first quarter of 2025.Adjusted EBITDA was $(7.0) million compared to $52.4 million in the first quarter of 2025.Diluted loss per share was $(0.38) for the first quarter of 2026 compared to diluted earnings per share of $0.63 in the first quarter of 2025.Adjusted diluted loss per share was $(0.17) for the first quarter of 2026 compared to adjusted diluted earnings per share of $0.69 in the first quarter of 2025. Financial Outlook:
For the second quarter of 2026, ODDITY expects net revenue to decline between 25 and 30% year-over-year. ODDITY expects Adjusted EBITDA will be between $8 and $10 million.
For the full year 2026, ODDITY expects Adjusted EBITDA to be positive.
Adjusted EBITDA, Adjusted EBITDA margin, Adjusted net (loss) income, Adjusted net (loss) income margin, Adjusted diluted (loss) earnings per share, and free cash flow are non-GAAP financial measures. Please see the sections titled “Non-GAAP Financial Measures” and “Reconciliations of GAAP to Non-GAAP Measures” below for more information regarding ODDITY’s use of non-GAAP financial measures and reconciliations to the most directly comparable GAAP measures. ODDITY has not provided a quantitative reconciliation of its Adjusted EBITDA outlook to the corresponding net income measure because the quantification of certain items included in the calculation of GAAP net income cannot be calculated or predicted at this time without unreasonable efforts. ODDITY is unable to address the probable significance of the unavailable reconciling items, which could have a potentially unpredictable, and potentially significant, impact on its future GAAP financial results.
The financial outlook figures presented above are forward-looking statements that are subject to a variety of assumptions and estimates. Actual results may differ materially from ODDITY’s financial outlook as a result of, among other things, the factors described under “Forward-Looking Statements” below.
Conference Call Details:
A conference call to discuss ODDITY’s Q1 2026 financial and business results and outlook is scheduled for today, June 2, 2026, at 8:30 a.m. ET. To participate, please dial 1-877-407-9208 (US) or 1-201-493-6784 (international). To access the call, please reference the company name and call title: ODDITY First Quarter 2026 Earnings Call. A webcast of the call will be accessible on the Investors section of ODDITY’s website at https://investors.oddity.com. A recording will be available shortly after the conclusion of the call. To access the replay, please dial 1-844-512-2921 (US) or 1-412-317-6671 (international). The access code for the replay is 13760709. An archive of the webcast will be available on the Investors section of ODDITY’s website for seven days following the call.
Non-GAAP Financial Measures:
In addition to the GAAP financial measures set forth in this press release, ODDITY has included the following non-GAAP financial measures: Adjusted EBITDA, Adjusted EBITDA margin, Adjusted net (loss) income, Adjusted net (loss) income margin, Adjusted diluted (loss) earnings per share and free cash flow. ODDITY believes these non-GAAP financial measures provide useful supplemental information to management and investors to help evaluate ODDITY’s business, measure its performance, identify trends, prepare financial projections and make business decisions.
ODDITY defines “Adjusted EBITDA” as net (loss) income before financial income, net, taxes on income, and depreciation and amortization as further adjusted to exclude share-based compensation expense and non-recurring items. “Adjusted EBITDA margin” is defined as Adjusted EBITDA divided by net revenue. ODDITY believes Adjusted EBITDA and Adjusted EBITDA margin are useful for financial and operational decision-making and as a means to evaluate period-to-period comparisons. By excluding certain items that may not be indicative of its recurring core operating results, ODDITY believes that Adjusted EBITDA and Adjusted EBITDA margin provide meaningful supplemental information regarding its performance. In addition, Adjusted EBITDA and Adjusted EBITDA margin are widely used by investors and securities analysts to measure a company’s operating performance without regard to items such as depreciation and amortization, interest expense, and interest income, which can vary substantially from company to company depending on their financing and capital structures and the method by which their assets were acquired.
ODDITY defines “Adjusted net (loss) income” as net (loss) income adjusted for the impact of share-based compensation, non-recurring items, one-time tax gains/losses and the tax effect of non-GAAP adjustments and “Adjusted net (loss) income margin” as Adjusted net (loss) income divided by net revenue. In addition, ODDITY defines “Adjusted diluted (loss) earnings per share” as Adjusted net (loss) income divided by diluted shares outstanding. ODDITY believes the presentations of Adjusted net (loss) income, Adjusted net (loss) income margin, and Adjusted diluted (loss) earnings per share are useful because they are frequently used by analysts, investors and other interested parties to evaluate companies in our industry. Further, ODDITY believes these measures are helpful in highlighting trends in our operating results, because they exclude the impact of items that are outside the control of management or not reflective of our ongoing operations and performance.
ODDITY defines “free cash flow” as net cash (used in) provided by operating activities less purchase of property and equipment.
ODDITY’s non-GAAP financial measures should be considered in addition to, not as a substitute for or in isolation from, its financial results prepared in accordance with U.S. GAAP. Other companies, including companies in our industry, may calculate these measures differently or not at all, which reduces their usefulness as comparative measures.
Reconciliations of non-GAAP financial measures to the most directly comparable GAAP measures are included with the financial tables at the end of this release under the heading “Reconciliations of GAAP to Non-GAAP Measures.”
Forward-Looking Statements:
Certain statements in this press release may constitute “forward-looking” statements and information, within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995 that relate to our current expectations and views of future events. In some cases, these forward-looking statements can be identified by words or phrases such as “aim,” “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “goal,” “hope,” “intend,” “may,” “objective,” “plan,” “potential,” “predict,” “project,” “shall,” “should,” “target,” “will,” “seek,” or similar words. The absence of these words does not mean that a statement is not forward-looking. These forward-looking statements address various matters, including ODDITY’s business strategy, market opportunity, ability to deliver superior products and experiences, ability to remedy the dislocation in our customer acquisition costs, potential long-term success and ODDITY’s outlook for the second quarter of 2026 and the full year ending December 31, 2026. These forward-looking statements are subject to risks, uncertainties and assumptions, some of which are beyond our control. In addition, these forward-looking statements reflect our current views with respect to future events and are not a guarantee of future performance. Actual outcomes may differ materially from the information contained in the forward-looking statements as a result of a number of factors, including, without limitation, the following: our ability to maintain the value of our brands; our ability to anticipate and respond to market trends and changes in consumer preferences; our ability to cost-effectively attract new customers (including by responding effectively to changes to algorithm-based bidding systems on key advertising platforms), retain existing customers and maintain or increase sales to those customers; our ability to maintain a strong base of engaged customers and content creators; the loss of suppliers or shortages or disruptions in the supply of raw materials or finished products; our ability to accurately forecast customer demand, manage our inventory, and plan for future expenses; our future rate of growth; competition; the fluctuating cost of raw materials; the illegal distribution and sale by third parties of counterfeit versions of our products or the unauthorized diversion by third parties of our products; changes in, or disruptions to, our shipping arrangements; our ability to manage our growth effectively; a general economic downturn or sudden disruption in business conditions; our ability to successfully introduce and effectively market new brands, or develop and introduce new, innovative, and updated products; foreign currency fluctuations; product returns; our ability to execute on our business strategy; our ability to maintain a high level of customer satisfaction; our ability to comply with and adapt to changes in laws and regulatory requirements applicable to our business, including with respect to regulation of the internet and e-commerce, evolving AI-technology related laws, tax laws, the anti-corruption, trade compliance, anti-money laundering, and terror finance and economic sanctions laws and regulations, consumer protection laws, and data privacy and security laws; failure of our products to comply with quality standards and risks related to product liability claims; trade restrictions; existing and potential tariffs; any data breach or other security incident of our information technology systems, or those of our third-party service providers or cyberattacks; risks related to online transactions and payment methods; any failure to obtain, maintain, protect, defend, or enforce our intellectual property rights; conditions in Israel and the Middle East generally, including as a result of geopolitical conflict; the concentration of our voting power as a result of our dual class structure; our status as a foreign private issuer; and other risk factors set forth in the section titled “Risk Factors” in our Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 17, 2026, and other documents filed with or furnished to the SEC. These statements reflect management’s current expectations regarding future events and operating performance and speak only as of the date of this press release. You should not put undue reliance on any forward-looking statements. Except as required by applicable law, we undertake no obligation to update or revise publicly any forward-looking statements.
About ODDITY:
ODDITY is a consumer tech company that builds and scales digital-first brands to disrupt the offline-dominated beauty and wellness industries. The company serves approximately 68 million users with its AI-driven online platform, deploying data science to identify consumer needs, and developing solutions in the form of beauty and wellness products. ODDITY owns IL MAKIAGE, SpoiledChild and METHODIQ. The company operates with business headquarters in New York City, an R&D center in Tel Aviv, Israel, and a biotechnology lab in Boston.
Weighted-average number of shares – basic (thousands)
56,317
56,003
Weighted-average number of shares – diluted (thousands)
56,317
60,322
Basic (loss) earnings per share
$
(0.38
)
$
0.68
Diluted (loss) earnings per share
$
(0.38
)
$
0.63
ODDITY TECH LTD.
CONSOLIDATED BALANCE SHEETS
U.S. dollar in thousands
March 31,
December 31,
2026
2025
(Unaudited)
(Audited)
ASSETS
CURRENT ASSETS:
Cash and cash equivalents
$
278,597
$
402,209
Marketable securities
17,113
11,170
Trade receivables
23,313
16,902
Inventories
147,976
135,181
Prepaid expenses and other current assets
33,089
36,336
Total current assets
500,088
601,798
LONG-TERM ASSETS:
Marketable securities
371,626
362,571
Property, plant and equipment, net
9,986
10,864
Deferred tax asset, net
30,299
27,693
Intangible assets, net
46,141
43,582
Goodwill
64,904
64,904
Operating lease right-of-use assets
22,701
22,311
Other assets
4,082
4,069
Total long-term assets
549,739
535,994
Total assets
$
1,049,827
$
1,137,792
ODDITY TECH LTD.
CONSOLIDATED BALANCE SHEETS
U.S. dollar in thousands
March 31,
December 31,
2026
2025
(Unaudited)
(Audited)
LIABILITIES AND SHAREHOLDERS’ EQUITY
CURRENT LIABILITIES:
Trade payables
$
65,252
$
75,957
Other accounts payable and accrued expenses
51,374
32,869
Operating lease liabilities, current
6,537
6,002
Total current liabilities
123,163
114,828
LONG-TERM LIABILITIES:
Operating lease liabilities, non-current
17,260
17,463
Exchangeable Note
585,222
584,368
Other long-term liabilities
25,272
24,638
Total liabilities
750,917
741,297
SHAREHOLDERS’ EQUITY:
Class A Ordinary shares
13
15
Class B Ordinary shares
3
3
Additional paid-in capital
4,230
77,571
Accumulated other comprehensive income
2,011
4,892
Retained earnings
292,653
314,014
Total shareholders’ equity
298,910
396,495
Total liabilities and shareholders’ equity
$
1,049,827
$
1,137,792
ODDITY TECH LTD.
CONSOLIDATED STATEMENTS OF CASH FLOWS
U.S. dollar in thousands
Three months ended March 31,
2026
2025
(Unaudited)
Cash flows from operating activities:
Net (loss) income
$
(21,361
)
$
37,831
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Depreciation and amortization
4,269
2,655
Share-based compensation
8,101
7,084
Deferred income taxes
(1,803
)
(302
)
Amortization of debt issuance costs
854
—
Change in trade receivables
(6,411
)
(4,289
)
Change in prepaid expenses and other receivables
2,772
(4,631
)
Change in inventories
(12,795
)
3,554
Change in trade payables
(10,704
)
41,642
Change in other accounts payable and accrued expenses
17,330
4,903
Change in operating lease right-of-use assets
1,943
1,969
Change in operating lease liability
(2,002
)
(2,049
)
Other
(427
)
(31
)
Net cash (used in) provided by operating activities
$
(20,234
)
$
88,336
Cash flows from investing activities:
Purchase of property, plant and equipment
(858
)
(1,002
)
Capitalization of software development costs and investment in other intangible assets
(4,197
)
(1,739
)
Investment in marketable securities, net
(18,435
)
(1,069
)
Other investing activities
—
(151
)
Net cash used in investing activities
(23,490
)
(3,961
)
Cash flows from financing activities:
Proceeds from exercise of options
13
1,931
Repurchase and retirement of ordinary shares
(80,055
)
—
Net cash (used in) provided by financing activities
(80,042
)
1,931
Effect of exchange rate fluctuations on cash and cash equivalents
106
284
Net (decrease) increase in cash, cash equivalents and restricted cash
(123,660
)
86,590
Cash, cash equivalents and restricted cash at the beginning of the period
402,279
50,347
Cash, cash equivalents and restricted cash at the end of the period
$
278,619
$
136,937
ODDITY TECH LTD.
Reconciliation of GAAP to Non-GAAP Measures
U.S. dollar in thousands (except per share data)
Three months ended
March 31,
2026
2025
(Unaudited)
Reconciliation of Net (Loss) Income and Adjusted EBITDA
Net (loss) income
$
(21,361
)
$
37,831
Financial income, net
(5,306
)
(2,647
)
Taxes on income
1,177
7,481
Depreciation and amortization
4,269
2,655
Share-based compensation
8,101
7,084
Other adjustments1
6,084
—
Adjusted EBITDA
$
(7,036
)
$
52,404
Reconciliation of Net (Loss) Income and Adjusted Net (Loss) Income
Net (loss) income
$
(21,361
)
$
37,831
Share-based compensation
8,101
7,084
Other adjustments1
6,084
—
Tax adjustments2
(2,608
)
(3,106
)
Adjusted net (loss) income
$
(9,784
)
$
41,809
¹ Represents costs of certain legal matters and employee actions outside the ordinary course of business.
2 Represents the tax impact of (a) the reconciling items above and (b) in the first quarter of 2025, other discrete tax items.
Three months ended
March 31,
2026
2025
(Unaudited)
Diluted (loss) earnings per share
$
(0.38
)
$
0.63
Adjusted diluted (loss) earnings per share
$
(0.17
)
$
0.69
Reconciliation of net cash (used in) provided by operating activities to free cash flow Three months ended
March 31,
2026
2025
(Unaudited)
Net cash (used in) provided by operating activities
$
(20,234
)
$
88,336
Purchase of property and equipment
(858
)
(1,002
)
Free cash flow
$
(21,092
)
$
87,334
ODDITY TECH LTD.
Supplemental Financial Information
U.S. dollar in thousands
Cash, cash equivalents, and investments
March 31,
December 31,
2026
2025
(Unaudited)
(Audited)
Cash, restricted cash, and cash equivalents
$
278,619
$
402,279
Marketable securities
388,739
373,741
Total cash and investments
$
667,358
$
776,020
Net revenue by sales channel Three months ended
March 31,
2026
2025
(Unaudited)
Online direct-to-consumer
$
193,055
$
261,053
Percent of net revenue
98
%
97
%
Other (Israel retail, marketing affiliates)
$
4,885
$
7,023
Percent of net revenue
2
%
3
%
Net Revenue
$
197,940
$
268,076
Note: ODDITY does not sell to resellers or distributors. Online direct-to-consumer revenues are generated directly by ODDITY through its online platform only (i.e., ILMAKIAGE.com, SpoiledChild.com, and METHODIQ.com). All revenue in Israel, including revenue generated in stores, online, and from beauty academies, is included in Other.
Oddity Tech (ODD - Free Report) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to earnings of $0.69 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -363.22%. A quarter ago, it was expected that this online retailer of cosmetics and beauty products would post earnings of $0.14 per share when it actually produced earnings of $0.2, delivering a surprise of +42.86%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Oddity Tech, which belongs to the Zacks Internet - Software industry, posted revenues of $197.94 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 5.48%. This compares to year-ago revenues of $268.08 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Oddity Tech shares have lost about 65.2% since the beginning of the year versus the S&P 500's gain of 11%.
What's Next for Oddity Tech?While Oddity Tech has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Oddity Tech was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.41 on $195.93 million in revenues for the coming quarter and $0.75 on $682.54 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Internet - Software is currently in the top 35% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Guidewire Software (GWRE - Free Report) , is yet to report results for the quarter ended April 2026. The results are expected to be released on June 4.
This provider of software to the insurance industry is expected to post quarterly earnings of $0.79 per share in its upcoming report, which represents a year-over-year change of -10.2%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Guidewire Software's revenues are expected to be $356.01 million, up 21.3% from the year-ago quarter.
Oddity Tech (ODD 3.19%) stock is getting hit with a big post-earnings sell-off in Tuesday's trading. The beauty industry software analytics company's share price was down 31.1% as of 2:10 p.m. ET.
Oddity reported its first-quarter results before the market opened today, and performance for the period was mixed. In addition to a wider-than-expected loss in the period, management's commentary and forward guidance were not encouraging. The stock is now down 87% over the last year.
Image source: Getty Images.
Oddity's Q1 report wasn't encouraging Oddity reported a non-GAAP (adjusted) loss of $0.17 per share in the first quarter, which was far worse than the average analyst estimate's call for a break-even quarter. While the company's revenue of $197.9 million in the period beat the average analyst estimate by roughly $10 million, sales still fell 26.2% year over year in the quarter.
Today's Change
(
-3.19
%) $
-0.35
Current Price
$
10.62
What's next for Oddity? For the current quarter, Oddity expects year-over-year sales to be down between 25% and 30%. Meanwhile, the company expects adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) to be between $8 million and $10 million for the quarter and also guided for positive adjusted EBITDA for the year. Oddity's sales declines aren't moderating to the extent that investors had hoped, and a big margins miss in Q1 and soft forward guidance aren't inspiring confidence.
Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Upcoming presentations at ENDO 2026 highlight Lundbeck's Focused Innovator strategy and continued expansion into rare neuroendocrine diseases with high unmet medical needsThe scientific program showcases Lundbeck's investigational neurohormonal and neuroimmunological targeted therapeutic candidates, asedebart and Lu AG22515, respectively Preliminary Phase II data for asedebart, an investigational anti-adrenocorticotropic hormone (ACTH) monoclonal antibody in Cushing's disease (CD), demonstrate Lundbeck's biomarker-supported approach to evaluating novel therapeutic mechanisms in rare endocrine disordersPreclinical characterization of the CD40L blocker Lu AG22515 will be shared as well as data from a patient study in thyroid eye disease (TED,) reflecting exploratory studies of CD40L modulation in autoimmune disease biology, with potential relevance to neuroinflammation implicated in several neurological and endocrine diseases, /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) today announced that new data will be presented at the 2026 Endocrine Society's Annual Meeting (ENDO), taking place June 13–16 in Chicago, Illinois, U.S. Lundbeck will present preliminary Phase II data for asedebart (Lu AG13909) in CD, reflecting Lundbeck's expansion into neuroendocrine diseases. In addition, preclinical and Phase Ib clinical exploratory findings on Lu AG22515 in patients with TED will be shared, providing insights into the broader therapeutic potential of CD40L pathway modulation across inflammatory and immunological disorders.
"Lundbeck's presence at ENDO 2026 reflects how we have expanded upon our neuroscience heritage in recent years. This involves pursuing biological drug targets within hormonal and immunological signaling pathways that offer the potential to deliver highly differentiated therapeutics for neurological and neuroendocrinology indications with high medical unmet need," said Johan Luthman, EVP and Head of Research & Development at Lundbeck. "Through this approach, we have made significant progress across our rare disease programs, enabling decisive, biomarker-supported patient studies that facilitate early development decisions, as exemplified by our ENDO 2026 scientific program."
Asedebart data provide insight into ACTH neutralization in Cushing's disease
Among the highlights are preliminary Phase II data for asedebart, an investigational anti-adrenocorticotropic hormone (ACTH) monoclonal antibody, being evaluated in adults with CD.
CD is a rare neuroendocrine disorder typically caused by an ACTH-secreting pituitary adenoma, leading to chronic excess cortisol production and substantial physical and neuropsychiatric burden.1,2 While surgery is the standard first-line treatment, many patients experience persistent or recurrent disease despite available pharmacologic options, and significant unmet need remains.
The Phase II data being presented include impact on urinary free cortisol (UFC) levels following individualized dose titration of asedebart, alongside safety and tolerability assessments, supporting further understanding of direct ACTH neutralization in CD.
The CD study builds on earlier Phase I findings in classic congenital adrenal hyperplasia (CAH) (ClinicalTrials.gov: NCT05669950), which showed pharmacodynamic effects on key adrenal steroid biomarkers. The CD data presented at ENDO add to Lundbeck's evaluation of targeting ACTH-driven endocrine conditions with links to brain function — using early clinical and pharmacodynamic evidence to assess therapeutic potential in areas of significant unmet need.
Asedebart has received Orphan Drug Designation (ODD) for CAH in the European Union and the United States as well as ODD in Japan for the treatment of patients with CD and CAH.
Lu AG22515 data provide insight into CD40L pathway biology
At ENDO, Lundbeck will also present preclinical characterization findings for the investigational CD40L blocker Lu AG22515. CD40L is a key immune signaling molecule heavily implicated in a wide range of immune disorders, neurology and potentially endocrine conditions.3 The presentation will describe the inhibitory effect and PK/PD profile of Lu AG22515, including effects on membrane-bound and soluble CD40L, B-cell activation and differentiation, proinflammatory cytokine production and in vivo antibody responses.
Additionally, clinical findings will be presented from an exploratory Phase Ib open label study on AG22515 in TED patients. TED is an autoimmune disorder that can cause proptosis, diplopia, pain, disfigurement and, in severe cases, visual impairment or vision loss.4 The presentation will cover three areas: pharmacodynamic assessments designed to evaluate CD40L pathway engagement, safety and tolerability, and preliminary clinical efficacy in TED, including effects on proptosis and other measures of disease activity. The data further enhance the understanding of CD40L pathway modulation in TED and other CD40L-mediated immune disorders.
Asedebart and Lu AG22515 are investigational drugs not approved for marketing by any regulatory authority worldwide, and the efficacy and safety of both molecules have not been established.
Details of Lundbeck presentations at ENDO 2026
Therapeutic Area
Presentation content
Presentation Type
Reference
Cushing's disease
Asedebart
Lu AG13909
A Phase II, Open-label, Dose-titration Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of the Novel Anti-ACTH Antibody Asedebart in Adults with Cushing's Disease
Oral presentation
Sun 14 June
14:45-15:00 CT
Room W183BC
Thyroid eye disease (TED)
Lu AG22515
Results From a Phase 1b Trial Evaluating CD40-Ligand Blocker Lu AG22515 in Patients with Moderate-to-Severe Thyroid Eye Disease
Oral presentation
Mon 15 June
14:15-14:30 CT
W184ABC
Thyroid eye disease (TED)
Lu AG22515
Preclinical Pharmacokinetic and Pharmacodynamic Profile of Lu AG22515, a CD40-Ligand Blocker in Development for Thyroid Eye Disease
Rapid-fire presentation and poster
Sun 14 June
09:00- 16:00 CT
ENDOExpo;
Poster floor
About Cushing's disease
Cushing's disease is a rare neuro-endocrine disorder caused by a pituitary adenoma that secretes excess ACTH, leading to chronic overproduction of cortisol.1 The condition is associated with significant morbidity and increased mortality, and patients may experience a wide range of physical and neuropsychiatric symptoms.2 First-line treatment is surgical removal of the tumor; however, not all patients are eligible, achieve sustained remission, or benefit fully from current available treatment options, highlighting an ongoing unmet need for effective and well-tolerated therapies.
About asedebart (Lu AG13909)
Asedebart is a humanized anti-ACTH monoclonal antibody designed specifically to recognize ACTH with high affinity. It blocks the binding of ACTH to the melanocortin 2 receptor in the adrenal glands and thereby inhibits the neurohormonal signalling of ACTH. This inhibition causes a decreased secretion of glucocorticoids, mineralocorticoids and androgens from the adrenal glands. 5,6 ACTH plays a key role in the biosynthesis of adrenal steroids7 and is therefore considered a promising therapeutic target in conditions characterized by elevated ACTH levels.6
About thyroid eye disease (TED)
Thyroid eye disease (TED) is a rare autoimmune condition associated with thyroid dysfunction, characterized by inflammation and expansion of retro-orbital tissues. Clinical manifestations include proptosis, double-vision, pain, swelling, and disfigurement, and in severe cases may lead to visual impairment or loss of vision. TED can have a substantial impact on daily functioning, quality of life and psychological wellbeing.4
Current treatments are not optimal for all patients and may be associated with significant adverse effects, highlighting the need for additional therapeutic approaches that target underlying autoimmune disease biology. 4
About Lu AG22515
Lu AG22515 is an investigational CD40L blocker being evaluated in CD40L mediated autoimmune diseases. Lu AG22515 is a recombinant fusion protein that binds CD40 ligand (CD40L) and human serum albumin (HSA) to extend half-life. By blocking the interaction between CD40L and the CD40 receptor, Lu AG22515 is designed to modulate a key immune co-stimulatory pathway involved in B-cell activation, antibody responses and inflammatory signaling.
Jens Høyer
Vice President, Head of Investor Relations [email protected]
+45 30 83 45 01
About H. Lundbeck A/S
Lundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases.
Brain disorders affect a large part of the world's population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, we hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments.
As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology.
We are committed to fighting stigma and we act to improve health equity. We strive to create long term value for our shareholders by making a positive contribution to patients, their families, and society as a whole.
Lundbeck has more than 5,000 employees in more than 20 countries and our products are available in more than 80 countries. For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us via LinkedIn.
References:
Lacroix A, Feelders RA, Stratakis CA, et al. Lancet. 2015;386(9996):913–927Sharma ST, Nieman LK, Feelders RA. Pituitary. 2015;18(2):188–194Ots HD, Tracz JA, Vinokuroff KE, et al. Int J Mol Sci. 2022;23(8):4115Dhaliwal NK, Razzaq L. Cureus. 2025;17(6):e86483.Lundbeck. Data on fileFeldhaus AL, et al. Endocrinology 2017;158(1):1-8Xing Y, et al. J Endocrinol 2011;209(3):327-35CONTACT:
H. Lundbeck A/S
Ottiliavej 9, 2500 Valby, Denmark
+45 3630 1311 [email protected]
This information was brought to you by Cision http://news.cision.com
View original content:https://www.prnewswire.com/news-releases/lundbeck-to-present-new-patient-data-on-neuroendocrine-and-neuroimmunology-programs-at-endo-2026-302796359.html
